losartan has been researched along with Cardiac Failure in 341 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ramipril and losartan exert a similar effect upon markers of heart failure and endogenous fibrinolysis, and, with DAPT, a more efficient antiplatelet effect in long term than DAPT alone." | 9.22 | Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial. ( Marinšek, M; Sinkovič, A, 2016) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 9.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "There have been no mortality/morbidity endpoint studies with losartan in Chinese heart failure patients." | 9.16 | A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor t ( Cai, NS; Dickstein, K; Hanson, ME; Hu, DY; Huang, J; Li, YS; Massaad, R; Zhu, WL, 2012) |
| " 3846 patients with heart failure of New York Heart Association class II-IV, left-ventricular ejection fraction 40% or less, and intolerance to angiotensin-converting-enzyme (ACE) inhibitors were randomly assigned to losartan 150 mg (n=1927) or 50 mg daily (n=1919)." | 9.14 | Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. ( Dickstein, K; Drexler, H; Guptha, S; Komajda, M; Konstam, MA; Malbecq, W; Martinez, FA; Neaton, JD; Poole-Wilson, PA; Riegger, GA; Smith, RD, 2009) |
| "To compare the effect of high and moderate doses of losartan on the primary endpoint of all-cause mortality and hospitalisation due to heart failure in patients (n = 3834) with symptomatic heart failure and an ejection fraction < or = 40% who are intolerant of ACE-inhibitor treatment." | 9.13 | Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. ( Dickstein, K; Drexler, H; Guptha, S; Justice, SJ; Komajda, M; Konstam, MA; Malbecq, W; Martinez, FA; Neaton, JD; Poole-Wilson, PA; Riegger, GA, 2008) |
| "4%) and New York Heart Association Class II-III heart failure symptoms, already receiving a beta-blocker and an ACEI, were randomly assigned to either open-label losartan (losartan group) or no additional drug (control group) in a 2:1 ratio and the patients were followed for 12 weeks." | 9.12 | Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy. ( Arslan, U; Balcioğlu, S; Cengel, A; Ozdemir, M; Türkoğlu, S, 2007) |
| "Fourteen patients with heart failure received enalapril (10 mg twice daily) or losartan (50 mg twice daily) in a randomized double-blind crossover trial." | 9.11 | Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. ( Cruden, NL; Fox, KA; Newby, DE; Webb, DJ; Witherow, FN, 2004) |
| "To retrospectively investigate elevation of serum potassium when spironolactone (25 or 50 mg/day) and furosemide were administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) to patients with chronic heart failure for 12 months and occurrence of hyperkalemia and hypokalemia because of concomitant administration of spironolactone plus an ACE-I or ARB and furosemide." | 9.11 | Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. ( Hirooka, K; Isobe, F; Saito, M; Takada, M; Yasumura, Y, 2005) |
| "To study the effect a combination of enalapril and losartan on life quality in patients with congestive heart failure (HF)." | 9.10 | [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure]. ( Berezin, AE; Vizir, VA, 2002) |
| "In the Evaluation of Losartan in the Elderly (ELITE) heart failure study, a survival benefit (primarily because of a reduction in sudden deaths) was observed in symptomatic patients treated with losartan compared with captopril." | 9.09 | Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II. ( Camm, AJ; Dickstein, K; Klinger, GH; Konstam, MA; Martinez, FA; Neaton, J; Pitt, B; Poole-Wilson, P; Riegger, G; Segal, R; Sharma, D; Thiyagarajan, B, 1999) |
| "Twelve patients with heart failure (11 male, 1 female, ages 59 to 81 years) were randomized to double-blind crossover treatment with enalapril 10 mg BID followed by losartan 25 mg BID, or the reverse, each for 5 weeks." | 9.09 | Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. ( Dargie, HJ; Davie, AP; McMurray, JJ, 1999) |
| "Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan." | 9.09 | Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. ( Brooksby, P; Cowley, AJ; Klinger, G; Pitt, B; Robinson, PJ; Segal, R, 1999) |
| "The Losartan Heart Failure ELITE Study recently found that in patients with symptomatic heart failure and a left ventricular ejection fraction of | 9.09 | The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. ( Carides, GW; Cook, JR; Dasbach, EJ; Gerth, WC; Murray, JF; Pitt, B; Rich, MW; Segal, R; Snavely, DB, 1999) |
| "To evaluate effectiveness of nonpeptide angiotensin-2 subtype-1 receptor antagonist losartan in therapy of symptomatic congestive heart failure in patients with ischemic heart disease, 116 patients were examined at the age of 36-62 (mean age 50." | 9.09 | [Losartan in therapy of chronic heart failure]. ( Berezin, AE; Vizir, VA, 2000) |
| "To compare the effects of losartan and captopril upon central and regional haemodynamics, neurohormones and exercise capacity in heart failure." | 9.09 | Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. ( Cowley, AJ; Harrison, M; Houghton, AR, 1999) |
| "To measure health-related quality-of-life (HRQoL) in elderly symptomatic heart failure patients following treatment with an angiotensin II receptor antagonist (losartan) vs." | 9.09 | Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. ( Cowley, AJ; Dasbach, EJ; Pitt, B; Rich, MW; Santanello, NC; Segal, R; Wiens, BL, 2000) |
| "The OPTIMAAL study was a multicenter, double-blind, randomized, parallel, trial in high-risk patients who were treated early after acute myocardial infarction that compared treatment with an angiotensin-converting enzyme inhibitor (captopril) and a selective angiotensin II antagonist (losartan) on survival and morbidity." | 9.09 | Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiote ( Dickstein, K; Kjekshus, J, 2001) |
| "The results suggest that losartan and enalapril are of comparable efficacy and tolerability in the short-term treatment of moderate or severe congestive heart failure." | 9.08 | Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. ( Chang, P; Dickstein, K; Hall, C; Haunsø, S; Kjekshus, J; Remes, J; Willenheimer, R, 1995) |
| "The aim of the present study was to assess the short- and long-term effects of multiple doses of the angiotensin II receptor antagonist losartan in heart failure." | 9.08 | Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. ( Awan, N; Cleland, J; Crozier, I; Dickstein, K; Frey, M; Ikram, H; Klinger, G; Makris, L; Stephen, N; Young, J, 1995) |
| "To determine whether specific angiotensin II receptor blockade with losartan offers safety and efficacy advantages in the treatment of heart failure over angiotensin-converting-enzyme (ACE) inhibition with captopril, the ELITE study compared losartan with captopril in older heart-failure patients." | 9.08 | Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) ( Chang, PI; Cowley, AJ; Deedwania, PC; Martinez, FA; Meurers, G; Ney, DE; Pitt, B; Segal, R; Snavely, DB; Thomas, I, 1997) |
| "This double-blind, placebo-controlled study investigated whether 12 weeks of treatment with the angiotensin II receptor blocker losartan influenced N-terminal proANF plasma levels in 129 chronic heart failure patients." | 9.08 | Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. ( Dickstein, K; Hall, C; Klinge, R; Polis, A, 1997) |
| "This study was designed to determine 1) whether 12-week oral administration of losartan, an angiotensin II receptor antagonist, in patients with heart failure is well tolerated; and 2) whether functional capacity and clinical status of patients with heart failure in whom treatment with an angiotensin-converting enzyme (ACE) inhibitor is replaced with losartan for 12 weeks will remain similar to that noted in patients in whom treatment with an ACE inhibitor is continued." | 9.08 | Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. ( Chang, PI; Elkayam, U; Krauss, D; Lang, RM; Makris, L; McKelvie, RS; Ney, DE; Vaughan, DE; Yellen, LG, 1997) |
| "The pharmacokinetics of a selective AT1-subtype, nonpeptide, orally active, angiotensin II receptor antagonist, losartan, were characterized in 11 patients with heart failure (New York Heart Association class II, n = 6; class III, n = 4; class IV, n = 1) after oral and intravenous administration." | 9.08 | Pharmacokinetics of intravenous and oral losartan in patients with heart failure. ( Colucci, WS; Emmert, SE; Furtek, CI; Lo, MW; Lu, H; Ritter, MA; Rucinska, E; Toh, J; Uretsky, BF, 1998) |
| "Eight patients with congestive heart failure, NYHA classes I through IV, were treated for 6 months with enalapril (E) 20 mg/d, and another 8 with losartan (L) 50 mg/d." | 9.08 | Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. ( Ambrosio, GB; Ceconi, C; Dalla Libera, L; Facchin, L; Leprotti, C; Serafini, F; Vescovo, G; Volterrani, M, 1998) |
| "Losartan causes acute local peripheral arteriolar vasodilation in patients with heart failure but not in healthy control subjects." | 9.08 | Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II. ( Boon, NA; Flapan, AD; Fox, KA; Goodfield, NE; Newby, DE; Webb, DJ, 1998) |
| "These data demonstrate that selective blockade of the angiotensin II receptor with losartan causes a favorable vasodilatory and neurohumoral response in patients with heart failure." | 9.07 | Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. ( DeKock, M; Dickstein, K; Fleck, E; Gottlieb, S; Kostis, J; LeJemtel, T; Levine, B, 1994) |
| "Blockade of the angiotensin II receptor with the antagonist losartan causes vasodilator and neurohormonal effects in patients with congestive heart failure." | 9.07 | Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. ( DeKock, M; Dickstein, K; Fleck, E; Gottlieb, SS; Kostis, J; LeJemtel, T; Levine, TB, 1993) |
| "The UK National Health Service (NHS) currently spends in excess of £250 million per annum on angiotensin II receptor blockers (ARBs) for the treatment of hypertension and heart failure; with candesartan currently dominating the market." | 8.87 | Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. ( Bodalia, PN; Grosso, AM; Hingorani, AD; Macallister, RJ; Moon, JC; Scott, MA, 2011) |
| "This is the third part in a series of papers dealing with various aspects of clinical pharmacology of the first AT(1)-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Blocker of angiotensin-1 receptor antagonist losartan. Part III. Experience in therapy for chronic heart failure and after acute myocardial infarction]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "This review summarizes existing data on losartan, an angiotensin II (AII)-receptor antagonist, and compares its potential role with that of ACE inhibitors in the management of patients with heart failure." | 8.81 | The role of losartan in the management of patients with heart failure. ( Dickstein, K, 2001) |
| "Clinical studies of heart failure utilizing losartan, an angiotensin-II receptor antagonist, found that this drug is well tolerated and demonstrates hemodynamic, neurohormonal, and symptomatic improvement." | 8.80 | Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. ( Buyse, M; Pitt, B; Rucinska, EJ; Sharma, D, 2000) |
| " Experience with losartan, the first of the selective AII receptor antagonists to be approved for clinical use, indicates that this approach is efficacious in all grades of hypertension and offers a more attractive and acceptable tolerability profile than other forms of antihypertensive medications." | 8.79 | Angiotensin II antagonism: a new avenue of hypertension management. ( Gavras, H, 1997) |
| " We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension." | 8.31 | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. ( Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG, 2023) |
| "Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)." | 7.91 | Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019) |
| "In a study conducted on 82 patients with a history of heart failure and hypertension who had been treated with an ARB but failed to reach the target blood pressure, ongoing oral ARB treatment was switched to a drug combination of losartan and hydrochlorothiazide (HCTZ)." | 7.80 | Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure. ( Aizawa, T; Amino, M; Deguchi, Y; Ikari, Y; Kanda, S; Tanabe, T; Yoshioka, K, 2014) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 7.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "To investigate the mechanisms of losartan- and exercise training-induced improvements on endothelial dysfunction in heart failure." | 7.79 | Exercise training and losartan improve endothelial function in heart failure rats by different mechanisms. ( Ellingsen, Ø; Haram, PM; Høydal, MA; Kemi, OJ; Wisløff, U, 2013) |
| "To assess the hypothesis that losartan use is associated with increased all-cause mortality in heart failure patients as compared with candesartan." | 7.78 | Association of treatment with losartan vs candesartan and mortality among patients with heart failure. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
| "This study tested the reversal of subcellular remodelling in heart failure due to myocardial infarction (MI) upon treatment with losartan, an angiotensin II receptor antagonist." | 7.78 | Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. ( Babick, A; Chapman, D; Dhalla, NS; Elimban, V; Zieroth, S, 2012) |
| "To investigate the possible effects of telmisartan and losartan on cardiac function in adriamycin (ADR)-induced heart failure in rats, and to explore the changes in plasma level of angiotensin-(1-7)[Ang-(1-7)] and myocardial expression of angiotensin II type 1/2 receptors (AT(1)R / AT(2)R) and Mas receptor caused by the two drugs." | 7.77 | Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure. ( Cao, K; Chen, XM; Huang, HJ; Huang, J; Lu, XZ; Qin, XY; Yang, XH; Yong, YH; Zheng, HJ; Zong, WN, 2011) |
| "This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial in which serum Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients with an acute myocardial infarction complicated by signs or symptoms of heart failure." | 7.75 | Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. ( Anker, SD; Belonje, AM; Dickstein, K; Ponikowski, P; van Veldhuisen, DJ; von Haehling, S; Voors, AA; Westenbrink, BD, 2009) |
| "The effects of endogenous angiotensin II (Ang II) and neuronal nitric oxide synthase (nNOS) on tonic sympathetic activity were studied in salt-sensitive hypertension-induced heart failure." | 7.75 | Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure. ( Kato, K; Kemuriyama, T; Maruyama, S; Nishida, Y; Ohta, H; Sato, Y; Tandai-Hiruma, M, 2009) |
| " Rats with congestive heart failure (CHF) have increased protein level of NKCC2, which can be normalized by angiotensin II receptor type-1 (AT(1)) blockade with losartan." | 7.74 | Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure. ( Brønd, L; Christensen, S; Hadrup, N; Jonassen, TE; Nielsen, JB; Nielsen, S; Praetorius, J; Torp, M, 2007) |
| " We employed rats with myocardial infarction (MI) to examine effects of an angiotensin-converting enzyme inhibitor, imidapril, on SR Ca(2+) transport, protein content, and gene expression." | 7.73 | Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment. ( Dhalla, NS; Netticadan, T; Ren, B; Saini, HK; Shao, Q; Takeda, N, 2005) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 7.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| "The purpose of the present study was to evaluate the effects of losartan and the combination of losartan and L-arginine on endothelial function and hemodynamic variables in patients with heart failure (HF)." | 7.73 | Effects of losartan + L-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease. ( Bykhovsy, E; Chernihovsky, T; Keren, G; Koifman, B; Megidish, R; Topilski, I; Zelmanovich, L, 2006) |
| "To investigate the effects of losartan on mRNA expression of myocardial sarcoplasmic reticulum calcium handling proteins (SERCA2, RyR2 and PLB) and the role of which in prevention of chronic heart failure in rabbit." | 7.73 | [Effect of losartan on sarcoplasmic reticulum Ca2+ handing proteins in heart failure rabbit]. ( Chen, G; Huang, CX; Xu, L; Yao, Y, 2006) |
| "Angiotensin II type I receptor antagonists (ARAs) have been tested in two large randomized trials, Evaluation of Losartan in the Elderly II (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT), and several other large trials are ongoing in the indication of chronic heart failure (CHF)." | 7.71 | Are angiotensin II receptor antagonists indicated in chronic heart failure? ( Komajda, M, 2002) |
| "The aim of this study was to evaluate the acute effects of E-3174, a human active metabolite of the AT1 receptor antagonist, losartan, on hemodynamic functions in dogs with severe heart failure (HF)." | 7.71 | Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. ( Hanada, K; Ikeda, T; Ikemoto, F; Kawai, N; Nakao, M; Nishikibe, M; Ohta, H; Suzuki, J, 2001) |
| "We sought to compare the protective efficacy of enalapril and losartan on lung diffusion in chronic heart failure (CHF)." | 7.71 | Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. ( Agostoni, P; Guazzi, M; Guazzi, MD, 2001) |
| "We sought to demonstrate non-angiotensin converting enzyme (ACE) dependent angiotensin II (AII) generating pathways in resistance arteries from patients with chronic heart failure (CHF)." | 7.71 | Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. ( Connell, JM; Hillier, C; McDonald, JE; McMurray, JJ; Padmanabhan, N; Petrie, MC, 2001) |
| "We studied the effects of chronic losartan (Los) treatment on contractile function of isolated right ventricular (RV) trabeculae from rat hearts 12 wk after left ventricular (LV) myocardial infarction (MI) had been induced by ligation of the left anterior descending artery at 4 wk of age." | 7.71 | Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction. ( Daniëls, MC; de Tombe, PP; Keller, RS, 2001) |
| "This study was designed to examine the effect of losartan treatment on renal tubular function in rats with mild congestive heart failure (CHF) induced by ligation of the left anterior descending artery." | 7.71 | Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure. ( Christensen, S; Janjua, NR; Jonassen, TE; Marcussen, N; Nielsen, S; Skøtt, O; Staahltoft, D, 2002) |
| "The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure." | 7.71 | Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002) |
| "We evaluate the acute hemodynamic and neurohormonal effects of losartan in 15 patients with symptomatic chronic heart failure (CHF), mean age 72+/-8 years, which were classified in two subgroups: (A) Patients with left ventricular ejection fraction (LVEF)< or =0." | 7.70 | Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure. ( Domínguez, J; García-Escribano, JR; Paule, A; Rodríguez-García, JL; Vázquez, M, 1999) |
| " We investigated the role in sympathetic nerve regulation of endogenous angiotensin (Ang)II in the brain in heart failure by examining the effect of losartan on the resting mean arterial blood pressure (MAP), heart rate (HR) and renal sympathetic nerve activity (RSNA) and the reflex reduction in RSNA elicited by acute volume expansion in conscious rabbits." | 7.70 | Blockade of central angiotensin II does not affect the reduction in renal sympathetic nerve activity following a volume load in heart failure rabbits. ( Badoer, E; McGrath, BP, 2000) |
| "In patients with heart failure a single dose of losartan resulted in increased angiotensin II and decreased aldosterone levels." | 7.69 | The acute and chronic effects of losartan in heart failure. ( Crozier, I; Ikram, H, 1995) |
| " In a single dose study in patients with heart failure, the AT1 antagonist losartan decreased mean arterial pressure and pulmonary arterial pressure and increased the cardiac index, with maximal effects at 25 mg/day." | 7.69 | Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. ( Fleck, E; Holzmeister, J; Neuss, M; Regitz-Zagrosek, V, 1995) |
| "Losartan, a recently developed nonpeptide angiotensin II (AII) receptor antagonist, was orally administered for 14 days to mice with viral myocarditis, beginning 7 days after encephalomyocarditis virus inoculation." | 7.69 | Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. ( Araki, M; Imai, S; Kanda, T; Kobayashi, I; Murata, K; Suzuki, T, 1995) |
| "We compared the effects pretreatment with the ACE inhibitor moexipril with those of the type 1 angiotensin (AT1)-receptor antagonist losartan on structural and functional cardiac parameters after myocardial infarction in rats." | 7.69 | Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. ( Adamiak, D; Kregel, KC; Mott, A; Redlich, T; Stauss, HM; Unger, T; Zhu, YC, 1994) |
| "Angioedema has not been associated with losartan therapy in hemodialysis patients, as it has been with angiotensin converting enzyme (ACE) inhibitors." | 7.69 | Angioedema associated with angiotensin II receptor antagonist losartan. ( Sharma, PK; Yium, JJ, 1997) |
| "Treatment with losartan increased left ventricular ejection fraction (baseline vs." | 6.71 | Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure. ( Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2004) |
| "Aldosterone has been identified as a critically important neurohormone with direct detrimental effects on the myocardium." | 6.41 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. ( Miller, AB; Srivastava, P, 2001) |
| " At the 48-week follow-up of the Evaluation of Losartan in the Elderly (ELITE) Study, the AT1 receptor antagonist losartan (at a dosage of 50 mg/day) was found to be superior to captopril 50 mg 3 times daily in terms of its effects on total mortality, total mortality and/or hospitalisation for CHF, and hospitalisation for any reason." | 6.40 | The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. ( Aronow, WS, 1998) |
| "Serum uric acid (SUA) is activated in catabolic, hypoxic, and inflammatory conditions characteristic of heart failure (HF) and is a source of reactive oxygen species." | 5.69 | High- versus low-dose losartan and uric acid: An analysis from HEAAL. ( Ferreira, JP; Kiernan, MS; Konstam, MA; Zannad, F, 2023) |
| "Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0." | 5.36 | Losartan reduces mortality in a genetic model of heart failure. ( Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010) |
| "Losartan was initiated one week after infarction and exercise training after four weeks, either as single interventions or combined." | 5.34 | Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan. ( Ellingsen, O; Fortin, D; Garnier, A; Haram, PM; Høydal, MA; Kemi, OJ; Ventura-Clapier, R, 2007) |
| "Losartan treatment after myocardial infarction reduced the incidence of cMI from 30." | 5.32 | Losartan inhibits myosin isoform shift after myocardial infarction in rats. ( Davidoff, AW; Elkassem, S; Saito, K; ter Keurs, HE; Zhang, ML, 2003) |
| "Overall, doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2." | 5.32 | Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. ( Aralica, G; Batelja, L; Blagaic, AB; Hanzevacki, JS; Konjevoda, P; Kusec, V; Lovric-Bencic, M; Rogic, D; Seiwerth, S; Sikiric, P, 2004) |
| "During severe congestive heart failure (CHF), a number of sodium-retaining and vasoconstricting mechanisms are activated, including the renin-angiotensin-aldosterone system." | 5.29 | Losartan improves the natriuretic response to ANF in rats with high-output heart failure. ( Abassi, ZA; Golomb, E; Keiser, HR; Kelly, G; Klein, H, 1994) |
| "Ramipril and losartan exert a similar effect upon markers of heart failure and endogenous fibrinolysis, and, with DAPT, a more efficient antiplatelet effect in long term than DAPT alone." | 5.22 | Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial. ( Marinšek, M; Sinkovič, A, 2016) |
| "This study investigated the dose-related effect of losartan on changes in renal function using data from the HEAAL (Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan) trial." | 5.20 | Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure. ( Gregory, D; Kiernan, MS; Kociol, R; Konstam, MA; Massaro, J; Rossignol, P; Sarnak, MJ; Zannad, F, 2015) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 5.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| " Herein, we aimed at assessing the association between visit-to-visit BP variability and outcomes in chronic heart failure (CHF) patients enrolled in the Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan (HEAAL)." | 5.20 | Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study. ( Girerd, N; Gregory, D; Konstam, MA; Massaro, J; Rossignol, P; Zannad, F, 2015) |
| "Short-term add-on therapy with losartan reduced B-type natriuretic peptide levels in patients hospitalized for decompensated severe heart failure and low cardiac output with inotrope dependence." | 5.19 | Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial. ( Barretto, AC; Brancalhão, EC; Cardoso, JN; Ochiai, ME; Oliveira, MT; Puig, RS; Vieira, KR, 2014) |
| "A total of 9,027 patients with hypertension and ECG-LVH and without a history of HF were randomized to losartan- or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension study." | 5.16 | Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "There have been no mortality/morbidity endpoint studies with losartan in Chinese heart failure patients." | 5.16 | A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor t ( Cai, NS; Dickstein, K; Hanson, ME; Hu, DY; Huang, J; Li, YS; Massaad, R; Zhu, WL, 2012) |
| "The relation of QRS over time to incident heart failure was examined in 8945 hypertensive patients without history of heart failure who were randomly assigned to losartan-based or atenolol-based treatment." | 5.14 | Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Okin, PM, 2009) |
| " 3846 patients with heart failure of New York Heart Association class II-IV, left-ventricular ejection fraction 40% or less, and intolerance to angiotensin-converting-enzyme (ACE) inhibitors were randomly assigned to losartan 150 mg (n=1927) or 50 mg daily (n=1919)." | 5.14 | Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. ( Dickstein, K; Drexler, H; Guptha, S; Komajda, M; Konstam, MA; Malbecq, W; Martinez, FA; Neaton, JD; Poole-Wilson, PA; Riegger, GA; Smith, RD, 2009) |
| "To compare the effect of high and moderate doses of losartan on the primary endpoint of all-cause mortality and hospitalisation due to heart failure in patients (n = 3834) with symptomatic heart failure and an ejection fraction < or = 40% who are intolerant of ACE-inhibitor treatment." | 5.13 | Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. ( Dickstein, K; Drexler, H; Guptha, S; Justice, SJ; Komajda, M; Konstam, MA; Malbecq, W; Martinez, FA; Neaton, JD; Poole-Wilson, PA; Riegger, GA, 2008) |
| "The relation of ECG strain and albuminuria to new-onset HF was examined in 7,786 hypertensive patients with no history of HF, who were randomly assigned to treatment with losartan or atenolol." | 5.13 | Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K, 2008) |
| " We also studied whether long-term treatment with isosorbide-5-mononitrate (IS-5-MN) in combination with standard HF therapy affects P-MDA levels in patients with evidence of left ventricular (LV) dysfunction following acute myocardial infarction (AMI)." | 5.12 | Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy. ( Gottsäter, A; Ohlin, AK; Ohlin, H; Tingberg, E, 2006) |
| "8479 hypertensive patients without history of heart failure who were randomly assigned to losartan or atenolol treatment." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2007) |
| "4%) and New York Heart Association Class II-III heart failure symptoms, already receiving a beta-blocker and an ACEI, were randomly assigned to either open-label losartan (losartan group) or no additional drug (control group) in a 2:1 ratio and the patients were followed for 12 weeks." | 5.12 | Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy. ( Arslan, U; Balcioğlu, S; Cengel, A; Ozdemir, M; Türkoğlu, S, 2007) |
| "Fourteen patients with heart failure received enalapril (10 mg twice daily) or losartan (50 mg twice daily) in a randomized double-blind crossover trial." | 5.11 | Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. ( Cruden, NL; Fox, KA; Newby, DE; Webb, DJ; Witherow, FN, 2004) |
| "We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria." | 5.11 | Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, S; Zhang, Z, 2004) |
| "We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive treatment with losartan and the first hospitalization for HF in patients with diabetes mellitus in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) studies." | 5.11 | Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. ( Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "To retrospectively investigate elevation of serum potassium when spironolactone (25 or 50 mg/day) and furosemide were administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) to patients with chronic heart failure for 12 months and occurrence of hyperkalemia and hypokalemia because of concomitant administration of spironolactone plus an ACE-I or ARB and furosemide." | 5.11 | Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. ( Hirooka, K; Isobe, F; Saito, M; Takada, M; Yasumura, Y, 2005) |
| "To study the effect a combination of enalapril and losartan on life quality in patients with congestive heart failure (HF)." | 5.10 | [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure]. ( Berezin, AE; Vizir, VA, 2002) |
| "Twenty patients with moderately severe chronic heart failure received enalapril 10 mg and losartan 50 mg on 2 separate occasions in a single-blind, randomized, crossover design." | 5.09 | Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. ( Flapan, AD; Goodfield, NE; Ludlam, CA; Newby, DE, 1999) |
| "In the Evaluation of Losartan in the Elderly (ELITE) heart failure study, a survival benefit (primarily because of a reduction in sudden deaths) was observed in symptomatic patients treated with losartan compared with captopril." | 5.09 | Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II. ( Camm, AJ; Dickstein, K; Klinger, GH; Konstam, MA; Martinez, FA; Neaton, J; Pitt, B; Poole-Wilson, P; Riegger, G; Segal, R; Sharma, D; Thiyagarajan, B, 1999) |
| "Twelve patients with heart failure (11 male, 1 female, ages 59 to 81 years) were randomized to double-blind crossover treatment with enalapril 10 mg BID followed by losartan 25 mg BID, or the reverse, each for 5 weeks." | 5.09 | Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. ( Dargie, HJ; Davie, AP; McMurray, JJ, 1999) |
| "Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan." | 5.09 | Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. ( Brooksby, P; Cowley, AJ; Klinger, G; Pitt, B; Robinson, PJ; Segal, R, 1999) |
| "The Losartan Heart Failure ELITE Study recently found that in patients with symptomatic heart failure and a left ventricular ejection fraction of | 5.09 | The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. ( Carides, GW; Cook, JR; Dasbach, EJ; Gerth, WC; Murray, JF; Pitt, B; Rich, MW; Segal, R; Snavely, DB, 1999) |
| "To evaluate effectiveness of nonpeptide angiotensin-2 subtype-1 receptor antagonist losartan in therapy of symptomatic congestive heart failure in patients with ischemic heart disease, 116 patients were examined at the age of 36-62 (mean age 50." | 5.09 | [Losartan in therapy of chronic heart failure]. ( Berezin, AE; Vizir, VA, 2000) |
| "To compare the effects of losartan and captopril upon central and regional haemodynamics, neurohormones and exercise capacity in heart failure." | 5.09 | Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. ( Cowley, AJ; Harrison, M; Houghton, AR, 1999) |
| "To measure health-related quality-of-life (HRQoL) in elderly symptomatic heart failure patients following treatment with an angiotensin II receptor antagonist (losartan) vs." | 5.09 | Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. ( Cowley, AJ; Dasbach, EJ; Pitt, B; Rich, MW; Santanello, NC; Segal, R; Wiens, BL, 2000) |
| "The OPTIMAAL study was a multicenter, double-blind, randomized, parallel, trial in high-risk patients who were treated early after acute myocardial infarction that compared treatment with an angiotensin-converting enzyme inhibitor (captopril) and a selective angiotensin II antagonist (losartan) on survival and morbidity." | 5.09 | Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiote ( Dickstein, K; Kjekshus, J, 2001) |
| "The results suggest that losartan and enalapril are of comparable efficacy and tolerability in the short-term treatment of moderate or severe congestive heart failure." | 5.08 | Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. ( Chang, P; Dickstein, K; Hall, C; Haunsø, S; Kjekshus, J; Remes, J; Willenheimer, R, 1995) |
| "The aim of the present study was to assess the short- and long-term effects of multiple doses of the angiotensin II receptor antagonist losartan in heart failure." | 5.08 | Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. ( Awan, N; Cleland, J; Crozier, I; Dickstein, K; Frey, M; Ikram, H; Klinger, G; Makris, L; Stephen, N; Young, J, 1995) |
| "The randomized angiotensin receptor antagonist--angiotensin converting enzyme (ACE)--Inhibitor Study (RAAS) was designed to test the hypothesis that the addition of an angiotensin II type 1 receptor blocking agent, losartan 50 mg/day, to an ACE-inhibitor, enalapril 10 mg twice a day (group 1), will be more effective than standard-dose enalapril 10 mg twice a day (group 2) or high-dose enalapril alone 20 mg twice a day (group 3), in blocking the activation of the renin angiotensin aldosterone system in patients with heart failure and left ventricular systolic dysfunction." | 5.08 | Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS). ( Chang, P; Dunlay, M; Grossman, W; Pitt, B; Timmermans, PB, 1996) |
| "To determine whether specific angiotensin II receptor blockade with losartan offers safety and efficacy advantages in the treatment of heart failure over angiotensin-converting-enzyme (ACE) inhibition with captopril, the ELITE study compared losartan with captopril in older heart-failure patients." | 5.08 | Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) ( Chang, PI; Cowley, AJ; Deedwania, PC; Martinez, FA; Meurers, G; Ney, DE; Pitt, B; Segal, R; Snavely, DB; Thomas, I, 1997) |
| "This double-blind, placebo-controlled study investigated whether 12 weeks of treatment with the angiotensin II receptor blocker losartan influenced N-terminal proANF plasma levels in 129 chronic heart failure patients." | 5.08 | Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. ( Dickstein, K; Hall, C; Klinge, R; Polis, A, 1997) |
| "This study was designed to determine 1) whether 12-week oral administration of losartan, an angiotensin II receptor antagonist, in patients with heart failure is well tolerated; and 2) whether functional capacity and clinical status of patients with heart failure in whom treatment with an angiotensin-converting enzyme (ACE) inhibitor is replaced with losartan for 12 weeks will remain similar to that noted in patients in whom treatment with an ACE inhibitor is continued." | 5.08 | Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. ( Chang, PI; Elkayam, U; Krauss, D; Lang, RM; Makris, L; McKelvie, RS; Ney, DE; Vaughan, DE; Yellen, LG, 1997) |
| "The pharmacokinetics of a selective AT1-subtype, nonpeptide, orally active, angiotensin II receptor antagonist, losartan, were characterized in 11 patients with heart failure (New York Heart Association class II, n = 6; class III, n = 4; class IV, n = 1) after oral and intravenous administration." | 5.08 | Pharmacokinetics of intravenous and oral losartan in patients with heart failure. ( Colucci, WS; Emmert, SE; Furtek, CI; Lo, MW; Lu, H; Ritter, MA; Rucinska, E; Toh, J; Uretsky, BF, 1998) |
| "Eight patients with congestive heart failure, NYHA classes I through IV, were treated for 6 months with enalapril (E) 20 mg/d, and another 8 with losartan (L) 50 mg/d." | 5.08 | Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. ( Ambrosio, GB; Ceconi, C; Dalla Libera, L; Facchin, L; Leprotti, C; Serafini, F; Vescovo, G; Volterrani, M, 1998) |
| "Losartan causes acute local peripheral arteriolar vasodilation in patients with heart failure but not in healthy control subjects." | 5.08 | Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II. ( Boon, NA; Flapan, AD; Fox, KA; Goodfield, NE; Newby, DE; Webb, DJ, 1998) |
| "These data demonstrate that selective blockade of the angiotensin II receptor with losartan causes a favorable vasodilatory and neurohumoral response in patients with heart failure." | 5.07 | Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. ( DeKock, M; Dickstein, K; Fleck, E; Gottlieb, S; Kostis, J; LeJemtel, T; Levine, B, 1994) |
| "Blockade of the angiotensin II receptor with the antagonist losartan causes vasodilator and neurohormonal effects in patients with congestive heart failure." | 5.07 | Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. ( DeKock, M; Dickstein, K; Fleck, E; Gottlieb, SS; Kostis, J; LeJemtel, T; Levine, TB, 1993) |
| "The UK National Health Service (NHS) currently spends in excess of £250 million per annum on angiotensin II receptor blockers (ARBs) for the treatment of hypertension and heart failure; with candesartan currently dominating the market." | 4.87 | Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. ( Bodalia, PN; Grosso, AM; Hingorani, AD; Macallister, RJ; Moon, JC; Scott, MA, 2011) |
| "Losartan is an effective antagonist of angiotensin II AT(1) receptors which has been shown to provide important clinical benefits in patients with hypertension, congestive heart failure and renal diseases." | 4.87 | Pharmacokinetic evaluation of losartan. ( Burnier, M; Wuerzner, G, 2011) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| "This is the third part in a series of papers dealing with various aspects of clinical pharmacology of the first AT(1)-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Blocker of angiotensin-1 receptor antagonist losartan. Part III. Experience in therapy for chronic heart failure and after acute myocardial infarction]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "This review summarizes existing data on losartan, an angiotensin II (AII)-receptor antagonist, and compares its potential role with that of ACE inhibitors in the management of patients with heart failure." | 4.81 | The role of losartan in the management of patients with heart failure. ( Dickstein, K, 2001) |
| "comparative data have shown losartan to be as effective as other antihypertensive agents in the treatment of elderly patients with hypertension." | 4.80 | Losartan: a review of its use, with special focus on elderly patients. ( McClellan, KJ; Simpson, KL, 2000) |
| "Clinical studies of heart failure utilizing losartan, an angiotensin-II receptor antagonist, found that this drug is well tolerated and demonstrates hemodynamic, neurohormonal, and symptomatic improvement." | 4.80 | Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. ( Buyse, M; Pitt, B; Rucinska, EJ; Sharma, D, 2000) |
| " Experience with losartan, the first of the selective AII receptor antagonists to be approved for clinical use, indicates that this approach is efficacious in all grades of hypertension and offers a more attractive and acceptable tolerability profile than other forms of antihypertensive medications." | 4.79 | Angiotensin II antagonism: a new avenue of hypertension management. ( Gavras, H, 1997) |
| "In patients with HF with reduced ejection fraction intolerant to angiotensin-converting enzyme inhibitors and treated with either high- or low-dose losartan, incident hypokalemia had a stronger association with poor outcomes than incident hyperkalemia." | 4.31 | High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL. ( Ferreira, JP; Kiernan, MS; Konstam, M; Rossignol, P; Zannad, F, 2023) |
| " We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension." | 4.31 | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. ( Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG, 2023) |
| "Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)." | 3.91 | Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019) |
| "Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy." | 3.88 | Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. ( Busby, J; Cardwell, CR; Hughes, C; Johnston, BT; McMenamin, Ú; Spence, A, 2018) |
| " We compared the effects of sudden stretch to SFR as well as to twitch and Ca2+ transient characteristics in rat myocardium with monocrotaline-induced heart failure with those in normal rat myocardium without and with inhibition of angiotensin II type-1 (AT1) receptors." | 3.88 | Inhibition of AT1 receptors by losartan affects myocardial slow force response in healthy but not in monocrotaline-treated young rats. ( Balakin, A; Lookin, O; Protsenko, Y, 2018) |
| "Chronic heart failure (CHF) increases sympathoexcitation through angiotensin II (ANG II) receptors (AT1R) in the paraventricular nucleus (PVN)." | 3.83 | Sympathoexcitation in Rats With Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus. ( Dong, Z; Huang, Q; Hultström, M; Lai, EY; Li, H; Qi, Y; Wang, H; Wang, R; Wei, X; Wilcox, CS; Wu, H; Zhou, R; Zhou, X, 2016) |
| "A multistate model to predict HF hospitalization and all-cause mortality was derived using data (n=3834) from the HEAAL study (Heart Failure Endpoint evaluation of Angiotensin II Antagonist Losartan), a multinational randomized trial in symptomatic patients with reduced left ventricular ejection fraction." | 3.83 | Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation. ( Huggins, GS; Kent, DM; Klaveren, Dv; Konstam, MA; Noubary, F; Upshaw, JN, 2016) |
| "In a study conducted on 82 patients with a history of heart failure and hypertension who had been treated with an ARB but failed to reach the target blood pressure, ongoing oral ARB treatment was switched to a drug combination of losartan and hydrochlorothiazide (HCTZ)." | 3.80 | Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure. ( Aizawa, T; Amino, M; Deguchi, Y; Ikari, Y; Kanda, S; Tanabe, T; Yoshioka, K, 2014) |
| "National reimbursement policies in Denmark were changed in November 2010 favouring a shift in angiotensin-II receptor blocker (ARB) treatment to generic losartan for heart failure (HF) patients." | 3.80 | Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies. ( Gislason, GH; Kristensen, SL; Køber, L; Lamberts, M; Selmer, C; Torp-Pedersen, C; von Kappelgaard, LM, 2014) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 3.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "Baseline and year-3 ECG LVH and left ventricular midwall shortening (MWS) were examined in 725 hypertensive patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic substudy." | 3.80 | Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure. ( Dahlöf, B; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K, 2014) |
| "Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension." | 3.79 | Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013) |
| "To investigate the mechanisms of losartan- and exercise training-induced improvements on endothelial dysfunction in heart failure." | 3.79 | Exercise training and losartan improve endothelial function in heart failure rats by different mechanisms. ( Ellingsen, Ø; Haram, PM; Høydal, MA; Kemi, OJ; Wisløff, U, 2013) |
| "8 years study treatment were assessed in 922 hypertensive patients in the Losartan Intervention For Endpoint reduction in hypertension echocardiography substudy." | 3.78 | Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Okin, PM; Wachtell, K, 2012) |
| "To assess the hypothesis that losartan use is associated with increased all-cause mortality in heart failure patients as compared with candesartan." | 3.78 | Association of treatment with losartan vs candesartan and mortality among patients with heart failure. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
| "This study tested the reversal of subcellular remodelling in heart failure due to myocardial infarction (MI) upon treatment with losartan, an angiotensin II receptor antagonist." | 3.78 | Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. ( Babick, A; Chapman, D; Dhalla, NS; Elimban, V; Zieroth, S, 2012) |
| " The aims of the present study were to investigate, whether at the time of cardiac failure the composition of fiber types of skeletal muscles was altered, what kind of alterations in glycolytic and oxidative enzyme activities occurred in different muscle fiber types and whether these were affected by the administration of the angiotensin II receptor blocker, losartan." | 3.77 | Changes in metabolic profile and population of skeletal muscle fibers of mice overexpressing calsequestrin: influence of losartan. ( Adams, V; Günther, S; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2011) |
| " Association of candesartan vs losartan with all-cause mortality in patients with heart failure." | 3.77 | [Remarkable results with candesartan]. ( Groenwold, RH; Rutten, FH, 2011) |
| "The activation of angiotensin II type 1 receptor (AT1R) in the brain plays a pivotal role in enhanced sympathetic drive in heart failure (HF)." | 3.77 | Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure. ( Hirooka, Y; Kishi, T; Ogawa, K; Sunagawa, K, 2011) |
| "To investigate the possible effects of telmisartan and losartan on cardiac function in adriamycin (ADR)-induced heart failure in rats, and to explore the changes in plasma level of angiotensin-(1-7)[Ang-(1-7)] and myocardial expression of angiotensin II type 1/2 receptors (AT(1)R / AT(2)R) and Mas receptor caused by the two drugs." | 3.77 | Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure. ( Cao, K; Chen, XM; Huang, HJ; Huang, J; Lu, XZ; Qin, XY; Yang, XH; Yong, YH; Zheng, HJ; Zong, WN, 2011) |
| "This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial in which serum Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients with an acute myocardial infarction complicated by signs or symptoms of heart failure." | 3.75 | Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. ( Anker, SD; Belonje, AM; Dickstein, K; Ponikowski, P; van Veldhuisen, DJ; von Haehling, S; Voors, AA; Westenbrink, BD, 2009) |
| "The effects of endogenous angiotensin II (Ang II) and neuronal nitric oxide synthase (nNOS) on tonic sympathetic activity were studied in salt-sensitive hypertension-induced heart failure." | 3.75 | Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure. ( Kato, K; Kemuriyama, T; Maruyama, S; Nishida, Y; Ohta, H; Sato, Y; Tandai-Hiruma, M, 2009) |
| "The purpose of this study was to evaluate the feasibility of noninvasive imaging of angiotensin II (AT) receptor upregulation in a mouse model of post-myocardial infarction (MI) heart failure (HF)." | 3.74 | Noninvasive imaging of angiotensin receptors after myocardial infarction. ( Bjurgert, E; Cuthbertson, A; Hofstra, L; Indrevoll, B; Kindberg, GM; Krasieva, TB; Lovhaug, D; Narula, J; Narula, N; Petersen, LB; Petrov, AD; Reutelingsperger, CP; Solbakken, M; Tromberg, BJ; Vannan, MA; Verjans, JW, 2008) |
| "Elderly patients with heart failure who were prescribed losartan had worse survival rates compared with those prescribed other commonly used ARBs." | 3.74 | Angiotensin II receptor blockers for the treatment of heart failure: a class effect? ( Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV, 2007) |
| " Rats with congestive heart failure (CHF) have increased protein level of NKCC2, which can be normalized by angiotensin II receptor type-1 (AT(1)) blockade with losartan." | 3.74 | Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure. ( Brønd, L; Christensen, S; Hadrup, N; Jonassen, TE; Nielsen, JB; Nielsen, S; Praetorius, J; Torp, M, 2007) |
| "The aim of this study was to determine whether reactive oxygen species (ROS) in the paraventricular nucleus (PVN) mediate both the cardiac sympathetic afferent reflex (CSAR) and angiotensin II-induced CSAR enhancement in chronic heart failure (CHF) rats." | 3.74 | Reactive oxygen species in the paraventricular nucleus mediate the cardiac sympathetic afferent reflex in chronic heart failure rats. ( Gao, XY; Han, Y; Shi, Z; Wang, W; Yu, Y; Zhang, F; Zhong, MK; Zhu, GQ, 2007) |
| " We employed rats with myocardial infarction (MI) to examine effects of an angiotensin-converting enzyme inhibitor, imidapril, on SR Ca(2+) transport, protein content, and gene expression." | 3.73 | Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment. ( Dhalla, NS; Netticadan, T; Ren, B; Saini, HK; Shao, Q; Takeda, N, 2005) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 3.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| " (3) Five clinical trials have evaluated angiotensin II receptor antagonists (candesartan, losartan and valsartan) in terms of their effect on mortality and on the risk of clinical deterioration in patients with symptomatic heart failure, but without severe renal failure, hyperkalemia or hypotension." | 3.73 | Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. ( , 2005) |
| "The purpose of the present study was to evaluate the effects of losartan and the combination of losartan and L-arginine on endothelial function and hemodynamic variables in patients with heart failure (HF)." | 3.73 | Effects of losartan + L-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease. ( Bykhovsy, E; Chernihovsky, T; Keren, G; Koifman, B; Megidish, R; Topilski, I; Zelmanovich, L, 2006) |
| "To investigate the effects of losartan on mRNA expression of myocardial sarcoplasmic reticulum calcium handling proteins (SERCA2, RyR2 and PLB) and the role of which in prevention of chronic heart failure in rabbit." | 3.73 | [Effect of losartan on sarcoplasmic reticulum Ca2+ handing proteins in heart failure rabbit]. ( Chen, G; Huang, CX; Xu, L; Yao, Y, 2006) |
| "The purpose of this study was to determine if the cardiac sympathetic afferent reflex (CSAR) was augmented in rats with coronary ligation-induced chronic heart failure (CHF), and if central angiotensin II (ANG II) was involved in this enhancement." | 3.71 | Central AT1 receptors are involved in the enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure. ( Wang, W; Zhu, GQ; Zucker, IH, 2002) |
| "Angiotensin II type I receptor antagonists (ARAs) have been tested in two large randomized trials, Evaluation of Losartan in the Elderly II (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT), and several other large trials are ongoing in the indication of chronic heart failure (CHF)." | 3.71 | Are angiotensin II receptor antagonists indicated in chronic heart failure? ( Komajda, M, 2002) |
| "The aim of this study was to evaluate the acute effects of E-3174, a human active metabolite of the AT1 receptor antagonist, losartan, on hemodynamic functions in dogs with severe heart failure (HF)." | 3.71 | Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. ( Hanada, K; Ikeda, T; Ikemoto, F; Kawai, N; Nakao, M; Nishikibe, M; Ohta, H; Suzuki, J, 2001) |
| "We sought to compare the protective efficacy of enalapril and losartan on lung diffusion in chronic heart failure (CHF)." | 3.71 | Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. ( Agostoni, P; Guazzi, M; Guazzi, MD, 2001) |
| "We sought to demonstrate non-angiotensin converting enzyme (ACE) dependent angiotensin II (AII) generating pathways in resistance arteries from patients with chronic heart failure (CHF)." | 3.71 | Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. ( Connell, JM; Hillier, C; McDonald, JE; McMurray, JJ; Padmanabhan, N; Petrie, MC, 2001) |
| "We studied the effects of chronic losartan (Los) treatment on contractile function of isolated right ventricular (RV) trabeculae from rat hearts 12 wk after left ventricular (LV) myocardial infarction (MI) had been induced by ligation of the left anterior descending artery at 4 wk of age." | 3.71 | Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction. ( Daniëls, MC; de Tombe, PP; Keller, RS, 2001) |
| "This study was designed to examine the effect of losartan treatment on renal tubular function in rats with mild congestive heart failure (CHF) induced by ligation of the left anterior descending artery." | 3.71 | Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure. ( Christensen, S; Janjua, NR; Jonassen, TE; Marcussen, N; Nielsen, S; Skøtt, O; Staahltoft, D, 2002) |
| "The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure." | 3.71 | Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002) |
| "In rats with congestive heart failure, type 1 angiotensin II receptor antagonist treatment (losartan) decreases basal renal sympathetic nerve activity and improves arterial baroreflex regulation of renal sympathetic nerve activity." | 3.70 | Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure. ( DiBona, GF; Jones, SY; Sawin, LL, 1998) |
| " Because brain "ouabain" may act by activating the brain renin-angiotensin system (RAS), the aim of the present study was to assess whether chronic treatment with the AT1-receptor blocker losartan given centrally normalizes the sympathetic hyperactivity and impairment of baroreflex function in Wistar rats with CHF postmyocardial infarction (MI)." | 3.70 | Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. ( Huang, BS; Leenen, FH; Zhang, W, 1999) |
| "We evaluate the acute hemodynamic and neurohormonal effects of losartan in 15 patients with symptomatic chronic heart failure (CHF), mean age 72+/-8 years, which were classified in two subgroups: (A) Patients with left ventricular ejection fraction (LVEF)< or =0." | 3.70 | Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure. ( Domínguez, J; García-Escribano, JR; Paule, A; Rodríguez-García, JL; Vázquez, M, 1999) |
| " This case report presents the successful treatment of severe heart failure with prednisone, glycosides and an angiotensin-1 receptor antagonist." | 3.70 | [Heart failure as a cardiac symptom of sarcoidosis. Successful treatment of heart failure with steroids, digitalis and an angiotensin-1-receptor antagonist in sarcoidosis]. ( Erbel, R; Kuntz, S; Oldenburg, O; Philipp, T; Sack, S; Schäfers, RF; Weber, F, 2000) |
| " We investigated the role in sympathetic nerve regulation of endogenous angiotensin (Ang)II in the brain in heart failure by examining the effect of losartan on the resting mean arterial blood pressure (MAP), heart rate (HR) and renal sympathetic nerve activity (RSNA) and the reflex reduction in RSNA elicited by acute volume expansion in conscious rabbits." | 3.70 | Blockade of central angiotensin II does not affect the reduction in renal sympathetic nerve activity following a volume load in heart failure rabbits. ( Badoer, E; McGrath, BP, 2000) |
| "In patients with heart failure a single dose of losartan resulted in increased angiotensin II and decreased aldosterone levels." | 3.69 | The acute and chronic effects of losartan in heart failure. ( Crozier, I; Ikram, H, 1995) |
| " In a single dose study in patients with heart failure, the AT1 antagonist losartan decreased mean arterial pressure and pulmonary arterial pressure and increased the cardiac index, with maximal effects at 25 mg/day." | 3.69 | Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. ( Fleck, E; Holzmeister, J; Neuss, M; Regitz-Zagrosek, V, 1995) |
| " We examined the effect of intravenous and intracerebroventricular angiotensin II AT receptor blockade with losartan on the arterial baroreflex regulation of ERSNA in conscious control (C) and congestive heart failure (CHF) rats." | 3.69 | ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. ( Brooks, VL; DiBona, GF; Jones, SY, 1995) |
| "Losartan, a recently developed nonpeptide angiotensin II (AII) receptor antagonist, was orally administered for 14 days to mice with viral myocarditis, beginning 7 days after encephalomyocarditis virus inoculation." | 3.69 | Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. ( Araki, M; Imai, S; Kanda, T; Kobayashi, I; Murata, K; Suzuki, T, 1995) |
| "We compared the effects pretreatment with the ACE inhibitor moexipril with those of the type 1 angiotensin (AT1)-receptor antagonist losartan on structural and functional cardiac parameters after myocardial infarction in rats." | 3.69 | Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. ( Adamiak, D; Kregel, KC; Mott, A; Redlich, T; Stauss, HM; Unger, T; Zhu, YC, 1994) |
| "We compared the effects of the angiotensin converting enzyme inhibitor, captopril, with those of the angiotensin II (Ang II) subtype-1 receptor antagonist, losartan, on hemodynamics and hormonal changes in congestive heart failure by rapid ventricular pacing on conscious dogs." | 3.69 | Blockade of the renin-angiotensin system in heart failure in conscious dogs. ( Kageyama, Y; Matsumoto, A; Murakami, M; Naitoh, M; Saruta, T; Suzuki, H; Tsujimoto, G, 1995) |
| "Angioedema has not been associated with losartan therapy in hemodialysis patients, as it has been with angiotensin converting enzyme (ACE) inhibitors." | 3.69 | Angioedema associated with angiotensin II receptor antagonist losartan. ( Sharma, PK; Yium, JJ, 1997) |
| "Hypertension is associated with an increased risk of diastolic dysfunction." | 2.77 | Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. ( Fukuda, S; Ishii, K; Ito, H; Iwakura, K; Kasayuki, N; Kihara, H; Nakamura, F; Shimada, K; Yoshikawa, J, 2012) |
| "In patients with heart failure and reduced left ventricular ejection fraction (HFrEF), renin-angiotensin-aldosterone system blockade reduces morbidity and mortality, but comes at an increased risk of adverse events (AEs)." | 2.77 | Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. ( Dickstein, K; Francis, G; Kiernan, MS; Komajda, M; Konstam, MA; Martinez, FA; Neaton, JD; Wentworth, D; Zannad, F, 2012) |
| "Treatment with losartan increased left ventricular ejection fraction (baseline vs." | 2.71 | Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure. ( Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2004) |
| "In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of renal function." | 2.71 | Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. ( Brenner, BM; Carides, GW; de Zeeuw, D; Dimitrov, BD; Hille, DA; Perna, A; Remuzzi, G; Ruggenenti, P; Shahinfar, S, 2004) |
| " This mechanism may be independent of direct AIIRA effects and may be due, in part, to increased bioavailability of nitric oxide." | 2.70 | Effects of chronic subdepressor dose of angiotensin II type 1 receptor antagonist on endothelium-dependent vasodilation in patients with congestive heart failure. ( Arakawa, N; Hiramori, K; Nakamura, M; Saito, S; Sugawara, S; Yoshida, H, 2002) |
| "Thus, strategies for the treatment of heart failure have focused on agents that block the RAS." | 2.44 | Anti-angiotensin therapy: new perspectives. ( Deswal, A; Mann, DL; Ramasubbu, K, 2007) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| "Aldosterone has been identified as a critically important neurohormone with direct detrimental effects on the myocardium." | 2.41 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. ( Miller, AB; Srivastava, P, 2001) |
| " Possible reasons for lack of ARB superiority include insufficient dosing of ARB, differences in effects mediated through angiotensin II type 2 receptors, interaction with beta-blockers, and bradykinin-mediated effects specific to ACE inhibitors." | 2.41 | Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn? ( Pitt, B, 2002) |
| "Losartan was the first drug in this class to become commercially available." | 2.40 | Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. ( Burrell, LM; Johnston, CI, 1997) |
| " At the 48-week follow-up of the Evaluation of Losartan in the Elderly (ELITE) Study, the AT1 receptor antagonist losartan (at a dosage of 50 mg/day) was found to be superior to captopril 50 mg 3 times daily in terms of its effects on total mortality, total mortality and/or hospitalisation for CHF, and hospitalisation for any reason." | 2.40 | The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. ( Aronow, WS, 1998) |
| "Their use in congestive heart failure and renal disease is under investigation." | 2.40 | Angiotensin-II receptor antagonists: their place in therapy. ( Kirk, JK, 1999) |
| "Losartan was demonstrated to be an effective antagonist of many AII-induced actions and an effective antihypertensive agent in many animal models of hypertension (HTN)." | 2.38 | Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. ( Eberhardt, RT; Frishman, WH; Kang, PM; Kevak, RM, 1993) |
| "Albuminuria was defined as urine albumin/creatinine ratio ≥30 mg/g." | 1.91 | Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy. ( Ahmad, MI; Chen, LY; Kazibwe, R; Singh, S; Soliman, EZ; Soliman, MZ, 2023) |
| "Treatment with bisoprolol slowed the heart rate, and treatment with losartan lowered mean arterial pressure, confirming adequate dosing, but none of the treatments improved RV function or arrested the progression of RV hypertrophy and failure compared with vehicle." | 1.40 | Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. ( Andersen, A; Andersen, S; Bogaard, HJ; de Man, FS; Holmboe, S; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Vildbrad, MD; Vonk-Noordegraaf, A, 2014) |
| "Treatment with losartan for MI rats significantly attenuated upregulated AT1R but not AT2R." | 1.39 | Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure. ( Cai, M; Chen, Y; Geng, D; Mai, Z; Wang, J; Wen, Z, 2013) |
| "Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0." | 1.36 | Losartan reduces mortality in a genetic model of heart failure. ( Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010) |
| "Losartan treatment decreases the activation of p42/44 MAPK to the uninfarcted control level and preserves normal LZ+ MYPT1 expression." | 1.35 | Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression. ( Ararat, E; Brozovich, FV, 2009) |
| "Hypertension is strongly associated with increased risk of subsequent heart failure." | 1.35 | [Hypertension and the heart]. ( Andersen, NH; Svendsen, TL; Wachtell, K, 2009) |
| "Losartan was initiated one week after infarction and exercise training after four weeks, either as single interventions or combined." | 1.34 | Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan. ( Ellingsen, O; Fortin, D; Garnier, A; Haram, PM; Høydal, MA; Kemi, OJ; Ventura-Clapier, R, 2007) |
| "Heart failure is a common medical condition affecting nearly 5 million people each year in the United States, of whom 500,000 are newly diagnosed." | 1.32 | Congestive heart failure: guidelines for the primary care physician. ( Baran, DA; Galin, I, 2003) |
| "Losartan treatment (2 mg/ml in drinking water, daily) was started at 4 weeks and continued for 12 weeks." | 1.32 | Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction. ( Farahmand, F; Kaur, K; Khaper, N; Li, T; Singal, PK, 2003) |
| "Losartan treatment after myocardial infarction reduced the incidence of cMI from 30." | 1.32 | Losartan inhibits myosin isoform shift after myocardial infarction in rats. ( Davidoff, AW; Elkassem, S; Saito, K; ter Keurs, HE; Zhang, ML, 2003) |
| "Cardiac remodelling associated with congestive heart failure typically involves dilatation of the ventricular cavities, cardiomyocyte hypertrophy and alterations of extracellular matrix." | 1.32 | Induction of myocardial biglycan in heart failure in rats--an extracellular matrix component targeted by AT(1) receptor antagonism. ( Ahmed, MS; Andersen G, GØ; Andersson, Y; Attramadal, H; Attramadal, T; Vinge, LE; Yndestad, A; Øie, E, 2003) |
| "A total of 172 patients with cardiac failure (CF) of functional class II-IV aged 46-62 years were studied." | 1.32 | [Prognostic value of elevation of plasma concentration of atrial natriuretic peptide in patients with cardiac failure. Results of a cohort study]. ( Berezin, AE; Vizir, VA, 2003) |
| "Overall, doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2." | 1.32 | Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. ( Aralica, G; Batelja, L; Blagaic, AB; Hanzevacki, JS; Konjevoda, P; Kusec, V; Lovric-Bencic, M; Rogic, D; Seiwerth, S; Sikiric, P, 2004) |
| "Since heart failure is also associated with attenuated responses to catecholamines, we examined the effects of imidapril, an ACE inhibitor, on the beta-adrenoceptor (beta-AR) signal transduction in the failing heart." | 1.32 | Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system. ( Dhalla, NS; Ren, B; Saini, HK; Sethi, R; Shao, Q; Takeda, N, 2004) |
| "Congestive heart failure was characterized by dyspnea, depressed hemodynamic function and presence of lung and liver congestion." | 1.31 | Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. ( Khaper, N; Singal, PK, 2001) |
| "Treatment with losartan resulted in significant decreases in plasma ANF and N-terminal proANF, whereas BNP did not change." | 1.30 | Cardiac secretion of atrial and brain natriuretic peptides in acute ischaemic heart failure in pigs: effect of angiotensin II receptor antagonism. ( Djøseland, O; Hall, C; Karlberg, BE; Klinge, R, 1997) |
| "Pretreatment with losartan abolished the significant difference between the two groups." | 1.30 | The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure. ( Kawada, T; Miyano, H; Sato, T; Shishido, T; Sugimachi, M; Sunagawa, K; Yoshimura, R, 1998) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| "During severe congestive heart failure (CHF), a number of sodium-retaining and vasoconstricting mechanisms are activated, including the renin-angiotensin-aldosterone system." | 1.29 | Losartan improves the natriuretic response to ANF in rats with high-output heart failure. ( Abassi, ZA; Golomb, E; Keiser, HR; Kelly, G; Klein, H, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 78 (22.87) | 18.2507 |
| 2000's | 164 (48.09) | 29.6817 |
| 2010's | 88 (25.81) | 24.3611 |
| 2020's | 11 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Almengló, C | 1 |
| Couselo-Seijas, M | 1 |
| Agra, RM | 1 |
| Varela-Román, A | 1 |
| García-Acuña, JM | 1 |
| González-Peteiro, M | 1 |
| González-Juanatey, JR | 1 |
| Eiras, S | 1 |
| Álvarez, E | 1 |
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Kovács, MG | 1 |
| Kovács, ZZA | 1 |
| Varga, Z | 1 |
| Szűcs, G | 1 |
| Freiwan, M | 1 |
| Farkas, K | 1 |
| Kővári, B | 1 |
| Cserni, G | 1 |
| Kriston, A | 1 |
| Kovács, F | 1 |
| Horváth, P | 1 |
| Földesi, I | 1 |
| Csont, T | 1 |
| Kahán, Z | 1 |
| Sárközy, M | 1 |
| Ferreira, JP | 3 |
| Konstam, M | 1 |
| Rossignol, P | 5 |
| Kiernan, MS | 4 |
| Zannad, F | 7 |
| Ermis, N | 1 |
| Ulutas, Z | 1 |
| Ozhan, O | 1 |
| Yildiz, A | 1 |
| Vardi, N | 1 |
| Colak, C | 1 |
| Parlakpinar, H | 1 |
| Konstam, MA | 14 |
| Ahmad, MI | 1 |
| Kazibwe, R | 1 |
| Soliman, MZ | 1 |
| Singh, S | 1 |
| Chen, LY | 1 |
| Soliman, EZ | 1 |
| Yoo, YG | 1 |
| Lim, MJ | 1 |
| Kim, JS | 1 |
| Jeong, HE | 1 |
| Ko, H | 1 |
| Shin, JY | 1 |
| Sykora, M | 1 |
| Kratky, V | 1 |
| Cervenka, L | 1 |
| Kopkan, L | 1 |
| Tribulova, N | 1 |
| Szeiffova Bacova, B | 1 |
| McMurray, JJV | 1 |
| Butler, J | 1 |
| Girerd, N | 2 |
| Sharma, A | 1 |
| Voors, AA | 3 |
| Lam, CSP | 1 |
| Packer, M | 1 |
| Aiglova, R | 1 |
| Taborsky, M | 2 |
| Lazarova, M | 1 |
| Pavlu, L | 1 |
| Danek, J | 1 |
| Precek, J | 1 |
| Schee, A | 1 |
| Gloger, V | 1 |
| Cernicek, V | 1 |
| Vicha, M | 1 |
| Skala, T | 1 |
| Wang, T | 2 |
| Gao, W | 1 |
| Xiao, K | 1 |
| Liu, Q | 2 |
| Jia, R | 2 |
| Azevedo, ER | 1 |
| Mak, S | 1 |
| Floras, JS | 2 |
| Parker, JD | 1 |
| Busby, J | 1 |
| McMenamin, Ú | 1 |
| Spence, A | 1 |
| Johnston, BT | 1 |
| Hughes, C | 1 |
| Cardwell, CR | 1 |
| Lookin, O | 1 |
| Balakin, A | 1 |
| Protsenko, Y | 1 |
| Pitt, B | 16 |
| Bakris, GL | 1 |
| Weir, MR | 1 |
| Freeman, MW | 1 |
| Lainscak, M | 1 |
| Mayo, MR | 1 |
| Garza, D | 1 |
| Zawadzki, R | 1 |
| Berman, L | 1 |
| Bushinsky, DA | 1 |
| Abukar, Y | 1 |
| Ramchandra, R | 2 |
| Hood, SG | 2 |
| McKinley, MJ | 1 |
| Booth, LC | 1 |
| Yao, ST | 1 |
| May, CN | 2 |
| Leenen, FHH | 1 |
| Ahmad, M | 1 |
| Marc, Y | 1 |
| Llorens-Cortes, C | 1 |
| Wen, Z | 1 |
| Cai, M | 1 |
| Mai, Z | 1 |
| Chen, Y | 1 |
| Geng, D | 1 |
| Wang, J | 3 |
| Kao, YH | 1 |
| Chen, YC | 1 |
| Chung, CC | 1 |
| Lien, GS | 1 |
| Chen, SA | 1 |
| Kuo, CC | 1 |
| Chen, YJ | 1 |
| Kim, HS | 1 |
| No, CW | 1 |
| Goo, SH | 1 |
| Cha, TJ | 1 |
| Antoniou, T | 1 |
| Camacho, X | 1 |
| Yao, Z | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Yu, XJ | 1 |
| Suo, YP | 1 |
| Qi, J | 1 |
| Yang, Q | 1 |
| Li, HH | 1 |
| Zhang, DM | 1 |
| Yi, QY | 1 |
| Zhang, J | 1 |
| Zhu, GQ | 3 |
| Zhu, Z | 1 |
| Kang, YM | 2 |
| Manni, ME | 1 |
| Zazzeri, M | 1 |
| Musilli, C | 1 |
| Bigagli, E | 1 |
| Lodovici, M | 1 |
| Raimondi, L | 1 |
| Borgdorff, MA | 1 |
| Bartelds, B | 1 |
| Dickinson, MG | 1 |
| Steendijk, P | 1 |
| Berger, RM | 1 |
| Hesse, U | 1 |
| Godman, B | 1 |
| Petzold, M | 1 |
| Martin, A | 1 |
| Malmström, RE | 1 |
| Llewellyn, TL | 1 |
| Sharma, NM | 5 |
| Zheng, H | 7 |
| Patel, KP | 6 |
| Bang, CN | 1 |
| Gerdts, E | 3 |
| Aurigemma, GP | 1 |
| Boman, K | 3 |
| de Simone, G | 1 |
| Dahlöf, B | 12 |
| Køber, L | 2 |
| Wachtell, K | 7 |
| Devereux, RB | 13 |
| Dobre, D | 1 |
| Gregory, D | 3 |
| Massaro, J | 3 |
| Kiernan, M | 1 |
| Kanda, S | 1 |
| Yoshioka, K | 1 |
| Amino, M | 1 |
| Deguchi, Y | 1 |
| Aizawa, T | 1 |
| Tanabe, T | 1 |
| Ikari, Y | 1 |
| Ochiai, ME | 1 |
| Brancalhão, EC | 1 |
| Puig, RS | 1 |
| Vieira, KR | 1 |
| Cardoso, JN | 1 |
| Oliveira, MT | 1 |
| Barretto, AC | 1 |
| Yu, H | 1 |
| Liu, B | 1 |
| Selmer, C | 1 |
| Lamberts, M | 1 |
| Kristensen, SL | 1 |
| von Kappelgaard, LM | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 1 |
| Andersen, S | 1 |
| Schultz, JG | 1 |
| Andersen, A | 1 |
| Ringgaard, S | 1 |
| Nielsen, JM | 1 |
| Holmboe, S | 1 |
| Vildbrad, MD | 1 |
| de Man, FS | 1 |
| Bogaard, HJ | 1 |
| Vonk-Noordegraaf, A | 1 |
| Nielsen-Kudsk, JE | 1 |
| Li, M | 1 |
| Zheng, C | 1 |
| Kawada, T | 2 |
| Inagaki, M | 1 |
| Uemura, K | 1 |
| Sugimachi, M | 2 |
| Okin, PM | 10 |
| Chen, A | 1 |
| Chen, YM | 1 |
| Sarnak, MJ | 1 |
| Kociol, R | 1 |
| Balderia, PG | 1 |
| Wongrakpanich, S | 1 |
| Patel, M | 1 |
| Stanek, M | 1 |
| Hille, DA | 3 |
| Kjeldsen, SE | 8 |
| Zhang, D | 1 |
| Liu, J | 1 |
| Tu, H | 1 |
| Muelleman, RL | 1 |
| Li, YL | 2 |
| Kelloniemi, A | 1 |
| Aro, J | 1 |
| Näpänkangas, J | 1 |
| Koivisto, E | 1 |
| Mustonen, E | 1 |
| Ruskoaho, H | 1 |
| Rysä, J | 1 |
| Wang, R | 1 |
| Huang, Q | 1 |
| Zhou, R | 1 |
| Dong, Z | 1 |
| Qi, Y | 1 |
| Li, H | 1 |
| Wei, X | 1 |
| Wu, H | 1 |
| Wang, H | 1 |
| Wilcox, CS | 1 |
| Hultström, M | 1 |
| Zhou, X | 1 |
| Lai, EY | 1 |
| Marinšek, M | 1 |
| Sinkovič, A | 1 |
| Upshaw, JN | 1 |
| Klaveren, Dv | 1 |
| Noubary, F | 1 |
| Huggins, GS | 1 |
| Kent, DM | 1 |
| Palevsky, PM | 1 |
| Zhang, JH | 1 |
| Seliger, SL | 1 |
| Emanuele, N | 1 |
| Fried, LF | 1 |
| Nandi, SS | 1 |
| Mishra, PK | 1 |
| Kamal, Z | 1 |
| Nordstad, MG | 1 |
| Molden, E | 1 |
| Poole-Wilson, PA | 5 |
| Dickstein, K | 18 |
| Drexler, H | 2 |
| Justice, SJ | 1 |
| Komajda, M | 5 |
| Malbecq, W | 2 |
| Martinez, FA | 7 |
| Neaton, JD | 4 |
| Riegger, GA | 3 |
| Guptha, S | 2 |
| Wei, SG | 1 |
| Yu, Y | 2 |
| Zhang, ZH | 2 |
| Weiss, RM | 2 |
| Felder, RB | 2 |
| Hauptman, PJ | 1 |
| Crozier, I | 2 |
| Ikram, H | 2 |
| Regitz-Zagrosek, V | 2 |
| Neuss, M | 2 |
| Holzmeister, J | 1 |
| Fleck, E | 4 |
| Carvalho, VO | 1 |
| Guimarães, GV | 2 |
| Bocchi, EA | 2 |
| Belonje, AM | 1 |
| Westenbrink, BD | 1 |
| von Haehling, S | 1 |
| Ponikowski, P | 2 |
| Anker, SD | 2 |
| van Veldhuisen, DJ | 3 |
| Anguita, M | 1 |
| Toledano, F | 1 |
| León, C | 1 |
| Castillo, JC | 1 |
| Kemuriyama, T | 1 |
| Tandai-Hiruma, M | 1 |
| Kato, K | 1 |
| Ohta, H | 3 |
| Maruyama, S | 2 |
| Sato, Y | 1 |
| Nishida, Y | 1 |
| Verjans, JW | 1 |
| Lovhaug, D | 1 |
| Narula, N | 1 |
| Petrov, AD | 1 |
| Indrevoll, B | 1 |
| Bjurgert, E | 1 |
| Krasieva, TB | 1 |
| Petersen, LB | 1 |
| Kindberg, GM | 1 |
| Solbakken, M | 1 |
| Cuthbertson, A | 1 |
| Vannan, MA | 1 |
| Reutelingsperger, CP | 1 |
| Tromberg, BJ | 1 |
| Hofstra, L | 1 |
| Narula, J | 1 |
| Ararat, E | 1 |
| Brozovich, FV | 1 |
| Klinge, R | 2 |
| Djøseland, O | 1 |
| Karlberg, BE | 1 |
| Hall, C | 3 |
| Andersen, NH | 1 |
| Svendsen, TL | 1 |
| Li, YF | 2 |
| Wang, W | 4 |
| Edelman, JM | 4 |
| Erokhina, IL | 1 |
| Okovityĭ, SV | 1 |
| Kulikov, AN | 1 |
| Kazachenko, AA | 1 |
| Emel'ianova, OI | 1 |
| Krum, H | 1 |
| Smith, RD | 1 |
| McMurray, JJ | 7 |
| Swedberg, K | 1 |
| Cleland, JG | 2 |
| Coletta, AP | 1 |
| Freemantle, N | 1 |
| Ahmed, D | 1 |
| Rubis, P | 1 |
| Clark, AL | 3 |
| Zhang, W | 2 |
| Elimban, V | 4 |
| Xu, YJ | 1 |
| Zhang, M | 1 |
| Nijjar, MS | 1 |
| Dhalla, NS | 8 |
| Xing, XQ | 1 |
| Xu, J | 1 |
| Lü, XW | 1 |
| Huang, Y | 1 |
| Zhu, PL | 1 |
| Kleiber, AC | 1 |
| Kang, SM | 1 |
| Oh, J | 1 |
| Hong, N | 1 |
| Erol, A | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Punkt, K | 2 |
| Kusche, T | 2 |
| Günther, S | 2 |
| Adams, V | 1 |
| Jones, LR | 2 |
| Neumann, J | 2 |
| Baba, HA | 1 |
| Hauptmann, S | 1 |
| Holzhausen, HJ | 1 |
| Grossmann, C | 1 |
| Gergs, U | 1 |
| Ogino, K | 2 |
| Kato, M | 2 |
| Furuse, Y | 1 |
| Kinugasa, Y | 1 |
| Kaetsu, Y | 1 |
| Mizuta, E | 1 |
| Sugihara, S | 1 |
| Ishida, K | 1 |
| Yanagihara, K | 1 |
| Hisatome, I | 2 |
| Shigemasa, C | 2 |
| Moon, JC | 2 |
| Flett, AS | 1 |
| Godman, BB | 1 |
| Grosso, AM | 2 |
| Wierzbicki, AS | 1 |
| Eklind-Cervenka, M | 1 |
| Benson, L | 2 |
| Dahlström, U | 1 |
| Edner, M | 1 |
| Rosenqvist, M | 1 |
| Lund, LH | 2 |
| Lymperopoulos, A | 1 |
| Rengo, G | 1 |
| Zincarelli, C | 1 |
| Kim, J | 1 |
| Koch, WJ | 1 |
| Oikarinen, L | 2 |
| Viitasalo, M | 2 |
| Toivonen, L | 2 |
| Nieminen, MS | 3 |
| Maejima, Y | 1 |
| Nobori, K | 1 |
| Ono, Y | 1 |
| Adachi, S | 1 |
| Suzuki, J | 3 |
| Hirao, K | 1 |
| Isobe, M | 1 |
| Ito, H | 2 |
| Sanada, S | 1 |
| Komuro, I | 3 |
| Bodalia, PN | 1 |
| Macallister, RJ | 1 |
| Hingorani, AD | 1 |
| Scott, MA | 1 |
| Minhas, R | 1 |
| Julius, S | 4 |
| Volpe, M | 2 |
| Taddei, S | 1 |
| Desvigne-Nickens, P | 1 |
| Burnier, M | 1 |
| Wuerzner, G | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 4 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 3 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Parving, HH | 2 |
| Lambers Heerspink, HJ | 1 |
| Rutten, FH | 1 |
| Groenwold, RH | 1 |
| Fruhwald, F | 1 |
| Pieske, B | 1 |
| Kaplan, N | 1 |
| Tofan, EF | 1 |
| Butorov, IV | 1 |
| Gonchar, VI | 1 |
| Nekula, GI | 1 |
| De Mello, WC | 2 |
| Meredith, PA | 1 |
| Jarvis, SC | 1 |
| Desai, RJ | 1 |
| Ashton, CM | 1 |
| Deswal, A | 2 |
| Morgan, RO | 1 |
| Mehta, HB | 1 |
| Chen, H | 1 |
| Aparasu, RR | 1 |
| Johnson, ML | 1 |
| Ogawa, K | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Sunagawa, K | 2 |
| Mehta, PP | 1 |
| Zong, WN | 1 |
| Yang, XH | 1 |
| Chen, XM | 1 |
| Huang, HJ | 1 |
| Zheng, HJ | 1 |
| Qin, XY | 1 |
| Yong, YH | 1 |
| Cao, K | 1 |
| Huang, J | 2 |
| Lu, XZ | 1 |
| Ishii, K | 1 |
| Kihara, H | 1 |
| Kasayuki, N | 1 |
| Nakamura, F | 1 |
| Shimada, K | 1 |
| Fukuda, S | 1 |
| Iwakura, K | 1 |
| Yoshikawa, J | 1 |
| Vondráková, D | 1 |
| Málek, F | 1 |
| Dvorák, J | 1 |
| Sedivá, L | 1 |
| Kupec, J | 1 |
| Petrů, J | 1 |
| Neuzil, P | 1 |
| Osborn, JW | 1 |
| Kuroki, MT | 1 |
| Watson, AM | 1 |
| Allen, AM | 1 |
| Svanström, H | 1 |
| Pasternak, B | 1 |
| Hviid, A | 1 |
| Yang, W | 1 |
| Joffe, MM | 1 |
| Larstorp, AC | 1 |
| Olsen, MH | 2 |
| Ibsen, H | 3 |
| Liu, X | 1 |
| Babick, A | 1 |
| Chapman, D | 2 |
| Zieroth, S | 1 |
| Hu, DY | 1 |
| Cai, NS | 1 |
| Zhu, WL | 1 |
| Li, YS | 1 |
| Massaad, R | 1 |
| Hanson, ME | 1 |
| Ruzicka, M | 1 |
| McReynolds, AJ | 1 |
| Coletta, E | 1 |
| Haddad, H | 1 |
| Davies, R | 1 |
| Leenen, FH | 2 |
| Wentworth, D | 1 |
| Francis, G | 1 |
| Kemi, OJ | 2 |
| Haram, PM | 2 |
| Høydal, MA | 2 |
| Wisløff, U | 2 |
| Ellingsen, Ø | 1 |
| Zucker, IH | 2 |
| Cocco, G | 1 |
| Kohn, S | 1 |
| Jerie, P | 1 |
| Ditiatkov, AE | 1 |
| Radzevich, AE | 1 |
| Tikhonov, VA | 1 |
| Zholnin, PA | 1 |
| Mal'gina, GV | 1 |
| Nakamura, M | 1 |
| Saito, S | 1 |
| Yoshida, H | 1 |
| Arakawa, N | 1 |
| Sugawara, S | 1 |
| Hiramori, K | 1 |
| Pascual Figal, DA | 1 |
| Morena Valenzuela, Gde L | 1 |
| Nicolás Ruiz, F | 1 |
| Tovar Zapata, I | 1 |
| Ruipérez Abizanda, JA | 1 |
| Valdés Chávarri, M | 1 |
| Kopp, UC | 1 |
| Cicha, MZ | 1 |
| Smith, LA | 1 |
| Massie, BM | 1 |
| Mareev, VIu | 1 |
| Shinohara, H | 2 |
| Fukuda, N | 1 |
| Soeki, T | 1 |
| Sakabe, K | 1 |
| Onose, Y | 1 |
| Tamura, Y | 1 |
| Zukowska-Szczechowska, E | 1 |
| Gosek, K | 1 |
| Grzeszczak, W | 1 |
| Chen, HH | 1 |
| Redfield, MM | 1 |
| Nordstrom, LJ | 1 |
| Cataliotti, A | 1 |
| Burnett, JC | 1 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Kubota, T | 1 |
| Takeshita, A | 1 |
| Kinugawa, K | 1 |
| Takahashi, T | 1 |
| Nagai, R | 1 |
| Terra, SG | 1 |
| DiBona, GF | 4 |
| Sawin, LL | 2 |
| Gschwend, S | 1 |
| Henning, RH | 1 |
| Pinto, YM | 1 |
| van Gilst, WH | 1 |
| Buikema, H | 1 |
| Sidorenko, BA | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Stetsenko, TM | 1 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Galin, I | 1 |
| Baran, DA | 1 |
| Umemoto, S | 1 |
| Kawahara, S | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| Khaper, N | 2 |
| Kaur, K | 1 |
| Li, T | 1 |
| Farahmand, F | 1 |
| Singal, PK | 2 |
| Zhang, ML | 1 |
| Elkassem, S | 1 |
| Davidoff, AW | 1 |
| Saito, K | 1 |
| ter Keurs, HE | 1 |
| Winkler, G | 1 |
| Jermendy, G | 1 |
| Matos, L | 1 |
| Vachiéry, JL | 1 |
| Ahmed, MS | 1 |
| Øie, E | 1 |
| Vinge, LE | 1 |
| Yndestad, A | 2 |
| Andersen G, GØ | 1 |
| Andersson, Y | 1 |
| Attramadal, T | 1 |
| Attramadal, H | 1 |
| Simko, F | 1 |
| Simko, J | 1 |
| Fabryova, M | 1 |
| Guo, X | 2 |
| Latini, R | 1 |
| Masson, S | 1 |
| Staszewsky, L | 1 |
| Maggioni, AP | 1 |
| Lindley, TE | 1 |
| Doobay, MF | 1 |
| Sharma, RV | 1 |
| Davisson, RL | 1 |
| Vizir, VA | 5 |
| Berezin, AE | 6 |
| Pfeffer, M | 1 |
| Ferrario, C | 1 |
| Abdelhamed, AI | 1 |
| Moore, M | 1 |
| Nesto, RW | 1 |
| Kinugawa, T | 1 |
| Osaki, S | 1 |
| Igawa, O | 1 |
| Yasumura, Y | 2 |
| Miyatake, K | 1 |
| Okamoto, H | 1 |
| Miyauchi, T | 1 |
| Kawana, M | 1 |
| Tsutamoto, T | 1 |
| Kitakaze, M | 1 |
| Matsubara, H | 2 |
| Takaoka, H | 1 |
| Anzai, T | 1 |
| Himeno, H | 1 |
| Yokoyama, H | 1 |
| Yokoya, K | 1 |
| Shintani, U | 1 |
| Hashimoto, K | 1 |
| Koretsune, Y | 1 |
| Nakamura, Y | 1 |
| Imai, K | 1 |
| Masaoka, Y | 1 |
| Sekiya, M | 1 |
| Shiraki, T | 1 |
| Ozono, K | 1 |
| Matsuoka, T | 1 |
| Miyao, Y | 1 |
| Nomura, F | 1 |
| Cruden, NL | 2 |
| Witherow, FN | 1 |
| Webb, DJ | 2 |
| Fox, KA | 3 |
| Newby, DE | 4 |
| Lovric-Bencic, M | 1 |
| Sikiric, P | 1 |
| Hanzevacki, JS | 1 |
| Seiwerth, S | 1 |
| Rogic, D | 1 |
| Kusec, V | 1 |
| Aralica, G | 1 |
| Konjevoda, P | 1 |
| Batelja, L | 1 |
| Blagaic, AB | 1 |
| Kumagai, H | 1 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Saruta, T | 2 |
| Tomiyama, H | 2 |
| Takata, Y | 1 |
| Yamashina, A | 1 |
| Keane, WF | 1 |
| Zhang, Z | 2 |
| Shahinfar, S | 3 |
| Snapinn, S | 1 |
| Cooper, ME | 1 |
| Mitch, WE | 1 |
| Brenner, BM | 3 |
| Shah, KR | 1 |
| Ganguly, PK | 1 |
| Netticadan, T | 2 |
| Arneja, AS | 1 |
| Gao, L | 1 |
| Schultz, HD | 1 |
| Liu, D | 1 |
| Cornish, KG | 1 |
| Sethi, R | 1 |
| Shao, Q | 3 |
| Ren, B | 3 |
| Saini, HK | 2 |
| Takeda, N | 3 |
| Ruggenenti, P | 1 |
| Perna, A | 1 |
| Dimitrov, BD | 1 |
| Carides, GW | 3 |
| Bos, R | 1 |
| Mougenot, N | 1 |
| Findji, L | 1 |
| Médiani, O | 1 |
| Vanhoutte, PM | 1 |
| Lechat, P | 1 |
| Tse, GH | 1 |
| Ludlam, CA | 2 |
| Megson, I | 1 |
| Tappia, PS | 1 |
| Ueland, T | 2 |
| Aukrust, P | 2 |
| Otterdal, K | 1 |
| Frøland, SS | 2 |
| Kjekshus, J | 4 |
| Gullestad, L | 2 |
| Damås, JK | 1 |
| Wu, ZJ | 1 |
| He, JG | 1 |
| Li, L | 1 |
| Li, YH | 1 |
| Cheng, XS | 1 |
| Ruan, YM | 1 |
| Liu, GZ | 1 |
| Kuwabara, Y | 1 |
| Erhardt, LR | 2 |
| Baruch, L | 1 |
| Kunamneni, P | 1 |
| Segal, R | 8 |
| Sharma, D | 4 |
| Dasbach, EJ | 3 |
| Riegger, G | 3 |
| Camm, AJ | 3 |
| Bradstreet, DC | 1 |
| Ikeda, LS | 1 |
| Santoro, EP | 1 |
| Liu, GF | 1 |
| Liu, K | 1 |
| Snavely, DB | 3 |
| Barrios Alonso, V | 1 |
| Escobar Cervantes, C | 1 |
| Calderón Montero, A | 1 |
| Tingberg, E | 1 |
| Ohlin, AK | 1 |
| Gottsäter, A | 1 |
| Ohlin, H | 1 |
| Carr, AA | 1 |
| Kowey, PR | 1 |
| Lindholm, LH | 2 |
| Lyle, PA | 1 |
| Snapinn, SM | 1 |
| Omland, T | 1 |
| Squire, IB | 1 |
| Saito, M | 1 |
| Takada, M | 1 |
| Hirooka, K | 1 |
| Isobe, F | 1 |
| Weber, MA | 1 |
| Baumgart, P | 1 |
| Krauser, DG | 1 |
| Koifman, B | 1 |
| Topilski, I | 1 |
| Megidish, R | 1 |
| Zelmanovich, L | 1 |
| Chernihovsky, T | 1 |
| Bykhovsy, E | 1 |
| Keren, G | 1 |
| Winkler, R | 1 |
| Zugck, C | 1 |
| Cicoira, M | 1 |
| Davos, CH | 1 |
| Banasiak, W | 1 |
| Zardini, P | 1 |
| Haass, M | 1 |
| Senges, J | 1 |
| Coats, AJ | 1 |
| Juhlin, T | 1 |
| Ottosson, H | 1 |
| Jönsson, BA | 1 |
| Höglund, P | 1 |
| Horita, Y | 1 |
| Taura, K | 1 |
| Taguchi, T | 1 |
| Furusu, A | 1 |
| Kohno, S | 1 |
| Yao, Y | 1 |
| Huang, CX | 1 |
| Chen, G | 1 |
| Xu, L | 1 |
| Hudson, M | 1 |
| Humphries, K | 1 |
| Tu, JV | 1 |
| Behlouli, H | 1 |
| Sheppard, R | 1 |
| Pilote, L | 1 |
| Yamamoto, K | 1 |
| Hori, M | 1 |
| Silva, CP | 1 |
| Bacal, F | 1 |
| Pires, PV | 1 |
| Mangini, S | 1 |
| Issa, VS | 1 |
| Moreira, SF | 1 |
| Chizzola, PR | 1 |
| Souza, GE | 1 |
| Mitsuyama, S | 1 |
| Kudo, Y | 1 |
| Akazawa, H | 1 |
| Garnier, A | 1 |
| Fortin, D | 1 |
| Ventura-Clapier, R | 1 |
| Ellingsen, O | 2 |
| Torp, M | 1 |
| Brønd, L | 1 |
| Hadrup, N | 1 |
| Nielsen, JB | 1 |
| Praetorius, J | 1 |
| Nielsen, S | 2 |
| Christensen, S | 2 |
| Jonassen, TE | 2 |
| Han, Y | 1 |
| Shi, Z | 1 |
| Zhang, F | 1 |
| Zhong, MK | 1 |
| Gao, XY | 1 |
| Harris, KE | 1 |
| Jern, S | 1 |
| Ferreira, JC | 1 |
| Bacurau, AV | 1 |
| Evangelista, FS | 1 |
| Coelho, MA | 1 |
| Oliveira, EM | 1 |
| Casarini, DE | 1 |
| Krieger, JE | 1 |
| Brum, PC | 1 |
| Ramasubbu, K | 1 |
| Mann, DL | 2 |
| Ozdemir, M | 1 |
| Arslan, U | 1 |
| Türkoğlu, S | 1 |
| Balcioğlu, S | 1 |
| Cengel, A | 1 |
| Tiurenkov, IN | 1 |
| Nazvanova, AN | 1 |
| Tchepurina, NG | 1 |
| Kheyfets, IA | 1 |
| Dugina, JL | 1 |
| Martyushev-Poklad, AV | 1 |
| Sergeeva, SA | 1 |
| Epstein, OI | 1 |
| Borch-Johnsen, K | 1 |
| Kageyama, S | 1 |
| Ma, Y | 1 |
| Elks, C | 1 |
| Zheng, JP | 1 |
| Yang, ZM | 1 |
| Francis, J | 2 |
| Jones, SY | 3 |
| Brooks, VL | 1 |
| Araki, M | 1 |
| Kanda, T | 1 |
| Imai, S | 1 |
| Suzuki, T | 1 |
| Murata, K | 1 |
| Kobayashi, I | 1 |
| Chang, P | 2 |
| Willenheimer, R | 1 |
| Haunsø, S | 1 |
| Remes, J | 1 |
| Stauss, HM | 1 |
| Zhu, YC | 1 |
| Redlich, T | 1 |
| Adamiak, D | 1 |
| Mott, A | 1 |
| Kregel, KC | 1 |
| Unger, T | 1 |
| van Zwieten, PA | 1 |
| Lie, KI | 1 |
| MacFadyen, RJ | 1 |
| Reid, JL | 1 |
| Sweet, CS | 1 |
| Rucinska, EJ | 2 |
| Awan, N | 1 |
| Cleland, J | 1 |
| Stephen, N | 1 |
| Frey, M | 1 |
| Young, J | 1 |
| Klinger, G | 2 |
| Makris, L | 2 |
| Gottlieb, S | 1 |
| Kostis, J | 2 |
| Levine, B | 1 |
| DeKock, M | 2 |
| LeJemtel, T | 2 |
| Hildebrandt, A | 1 |
| Eberhardt, RT | 1 |
| Kevak, RM | 1 |
| Kang, PM | 1 |
| Frishman, WH | 1 |
| Abassi, ZA | 1 |
| Kelly, G | 1 |
| Golomb, E | 1 |
| Klein, H | 1 |
| Keiser, HR | 1 |
| Foote, EF | 1 |
| Halstenson, CE | 1 |
| Gottlieb, SS | 1 |
| Levine, TB | 1 |
| Awan, NA | 1 |
| Mason, DT | 1 |
| Murakami, M | 1 |
| Suzuki, H | 1 |
| Naitoh, M | 1 |
| Matsumoto, A | 1 |
| Kageyama, Y | 1 |
| Tsujimoto, G | 1 |
| Grossman, W | 1 |
| Dunlay, M | 1 |
| Timmermans, PB | 1 |
| Krasnikova, TL | 1 |
| Pichler, M | 1 |
| Klein, W | 2 |
| Huber, K | 1 |
| Pachinger, O | 1 |
| Meurers, G | 1 |
| Cowley, AJ | 4 |
| Thomas, I | 2 |
| Deedwania, PC | 1 |
| Ney, DE | 2 |
| Chang, PI | 2 |
| Sharma, PK | 1 |
| Yium, JJ | 1 |
| Jensen, BV | 1 |
| Nielsen, SL | 1 |
| Sechi, LA | 1 |
| Catena, C | 1 |
| Bartoli, E | 1 |
| Fournier, A | 1 |
| Achard, JM | 1 |
| Fernandez, LA | 1 |
| Ball, SG | 1 |
| Burrell, LM | 1 |
| Johnston, CI | 1 |
| Polis, A | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Rakugi, H | 2 |
| Ogihara, T | 2 |
| Gavras, H | 1 |
| Lang, RM | 1 |
| Elkayam, U | 1 |
| Yellen, LG | 1 |
| Krauss, D | 1 |
| McKelvie, RS | 1 |
| Vaughan, DE | 2 |
| Hunyady, L | 1 |
| Nagy, L | 1 |
| Peczkowska, M | 1 |
| Kabat, M | 1 |
| Janaszek-Sitkowska, H | 1 |
| Guazzi, M | 3 |
| Melzi, G | 1 |
| Agostoni, P | 3 |
| Aronow, WS | 1 |
| Lo, MW | 1 |
| Toh, J | 1 |
| Emmert, SE | 1 |
| Ritter, MA | 1 |
| Furtek, CI | 1 |
| Lu, H | 1 |
| Colucci, WS | 1 |
| Uretsky, BF | 1 |
| Rucinska, E | 1 |
| Mori, Y | 1 |
| Masaki, H | 1 |
| Inada, M | 1 |
| Sato, T | 1 |
| Yoshimura, R | 1 |
| Shishido, T | 1 |
| Miyano, H | 1 |
| Fushteĭ, IM | 1 |
| Struthers, AD | 1 |
| Vescovo, G | 1 |
| Dalla Libera, L | 1 |
| Serafini, F | 1 |
| Leprotti, C | 1 |
| Facchin, L | 1 |
| Volterrani, M | 1 |
| Ceconi, C | 1 |
| Ambrosio, GB | 1 |
| Goodfield, NE | 2 |
| Flapan, AD | 2 |
| Boon, NA | 1 |
| Hamroff, G | 1 |
| Katz, SD | 1 |
| Mancini, D | 1 |
| Blaufarb, I | 1 |
| Bijou, R | 1 |
| Patel, R | 1 |
| Jondeau, G | 1 |
| Olivari, MT | 1 |
| Thomas, S | 1 |
| Le Jemtel, TH | 1 |
| Doba, N | 1 |
| Nakayama, T | 1 |
| Baan, J | 1 |
| Su, J | 1 |
| Barbe, F | 1 |
| Houël, R | 1 |
| Guyene, TT | 1 |
| Crozatier, B | 1 |
| Hittinger, L | 1 |
| Huang, BS | 1 |
| Kirk, JK | 1 |
| Poole-Wilson, P | 1 |
| Klinger, GH | 2 |
| Neaton, J | 2 |
| Thiyagarajan, B | 2 |
| Davie, AP | 2 |
| Dargie, HJ | 1 |
| Brooksby, P | 1 |
| Robinson, PJ | 1 |
| Rodríguez-García, JL | 1 |
| Paule, A | 1 |
| Domínguez, J | 1 |
| García-Escribano, JR | 1 |
| Vázquez, M | 1 |
| Rich, MW | 2 |
| Gerth, WC | 1 |
| Cook, JR | 1 |
| Murray, JF | 1 |
| Satomi, T | 1 |
| Ikemoto, F | 2 |
| Nishikibe, M | 2 |
| Palermo, P | 1 |
| Pontone, G | 1 |
| Susini, F | 1 |
| Topol, E | 1 |
| White, M | 1 |
| Richer, C | 1 |
| Gervais, M | 1 |
| Fornes, P | 1 |
| Giudicelli, JF | 1 |
| Anguita Sánchez, M | 1 |
| Coca, A | 1 |
| Giner, V | 1 |
| Leary, AC | 1 |
| MacDonald, TM | 1 |
| Petkun, W | 1 |
| Berger, D | 1 |
| Witte, K | 1 |
| Thackray, S | 1 |
| Banerjee, T | 1 |
| Oldenburg, O | 1 |
| Schäfers, RF | 1 |
| Kuntz, S | 1 |
| Sack, S | 1 |
| Erbel, R | 1 |
| Philipp, T | 1 |
| Weber, F | 1 |
| Simpson, KL | 1 |
| McClellan, KJ | 1 |
| Velazquez, EJ | 1 |
| Califf, RM | 1 |
| Patten, RD | 1 |
| Ramahi, T | 1 |
| La Bresh, K | 1 |
| Goldman, S | 1 |
| Lewis, W | 1 |
| Gradman, A | 1 |
| Self, KS | 1 |
| Bittner, V | 1 |
| Rand, W | 1 |
| Kinan, D | 1 |
| Smith, JJ | 1 |
| Ford, T | 1 |
| Udelson, JE | 1 |
| LeClair, BM | 1 |
| Petretta, M | 1 |
| Spinelli, L | 1 |
| Marciano, F | 1 |
| Apicella, C | 1 |
| Vicario, ML | 1 |
| Testa, G | 1 |
| Bonaduce, D | 1 |
| Badoer, E | 1 |
| McGrath, BP | 1 |
| Einecke, D | 1 |
| Brown, NJ | 1 |
| Houghton, AR | 1 |
| Harrison, M | 1 |
| Trojian, TH | 1 |
| Jackson, EA | 1 |
| Buyse, M | 1 |
| Kromer, EP | 1 |
| Hall, A | 1 |
| Meyer, FP | 1 |
| Gansevoort, RT | 1 |
| Lye, M | 1 |
| Mahé, I | 1 |
| Kawai, H | 1 |
| Stevens, SY | 1 |
| Liang, CS | 1 |
| Hao, J | 1 |
| Wang, B | 1 |
| Jones, SC | 1 |
| Jassal, DS | 1 |
| Dixon, IM | 1 |
| Wiens, BL | 1 |
| Santanello, NC | 1 |
| Porcu, M | 1 |
| Orrù, P | 1 |
| Martineau, P | 1 |
| Goulet, J | 1 |
| Hanada, K | 1 |
| Kawai, N | 1 |
| Ikeda, T | 1 |
| Nakao, M | 1 |
| Guazzi, MD | 1 |
| Berry, C | 1 |
| Norrie, J | 1 |
| Jamali, AH | 1 |
| Tang, WH | 1 |
| Khot, UN | 1 |
| Fowler, MB | 1 |
| Cheng, CP | 2 |
| Ukai, T | 1 |
| Onishi, K | 1 |
| Ohte, N | 1 |
| Suzuki, M | 1 |
| Zhang, ZS | 1 |
| Cheng, HJ | 1 |
| Tachibana, H | 1 |
| Igawa, A | 1 |
| Little, WC | 3 |
| Petrie, MC | 1 |
| Padmanabhan, N | 1 |
| McDonald, JE | 1 |
| Hillier, C | 1 |
| Connell, JM | 1 |
| Miller, AB | 1 |
| Srivastava, P | 1 |
| Fruhwald, FM | 1 |
| Kickenweiz, E | 1 |
| Zweiker, R | 1 |
| Kitzman, DW | 1 |
| Düsing, R | 1 |
| Auer, JW | 1 |
| Berent, R | 1 |
| Eber, B | 1 |
| Daniëls, MC | 1 |
| Keller, RS | 1 |
| de Tombe, PP | 1 |
| Gurlek, A | 1 |
| Kilickap, M | 1 |
| Dincer, I | 1 |
| Dandachi, R | 1 |
| Tutkak, H | 1 |
| Oral, D | 1 |
| Giannattasio, C | 1 |
| Achilli, F | 1 |
| Grappiolo, A | 1 |
| Failla, M | 1 |
| Meles, E | 1 |
| Gentile, G | 1 |
| Calchera, I | 1 |
| Capra, A | 1 |
| Baglivo, J | 1 |
| Vincenzi, A | 1 |
| Sala, L | 1 |
| Mancia, G | 1 |
| Rumley, A | 1 |
| Lowe, GD | 1 |
| Staahltoft, D | 1 |
| Janjua, NR | 1 |
| Skøtt, O | 1 |
| Marcussen, N | 1 |
| Loennechen, JP | 1 |
| Falck, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and[NCT01371747] | Phase 2 | 324 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Short-term add-on Therapy With Angiotensin Receptor Blocker for End-stage Inotrope-dependent Heart Failure Patients: B-type Natriuretic Peptide Reduction in a Randomized Clinical Trial[NCT01857999] | Phase 4 | 21 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment[NCT00090259] | Phase 3 | 3,834 participants (Actual) | Interventional | 2001-12-19 | Completed | ||
| [NCT00000609] | Phase 3 | 0 participants | Interventional | 1997-05-31 | Completed | ||
| Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors[NCT00663377] | Phase 4 | 16 participants (Anticipated) | Interventional | 2006-04-30 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function[NCT00001628] | Phase 3 | 36 participants | Interventional | 1997-07-31 | Completed | ||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Least squares mean changes from Baseline to Day 3 were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Day 3
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.26 |
| Stratum 1: 16.8 g/d Patiromer | -0.28 |
| Stratum 1: 25.2 g/d Patiromer | -0.31 |
| Stratum 2: 16.8 g/d Patiromer | -0.65 |
| Stratum 2: 25.2 g/d Patiromer | -0.59 |
| Stratum 2: 33.6 g/d Patiromer | -0.53 |
Least square mean changes from Baseline to Week 4/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 4 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.51 |
| Stratum 1: 25.2 g/d Patiromer | -0.55 |
| Stratum 2: 16.8 g/d Patiromer | -0.87 |
| Stratum 2: 25.2 g/d Patiromer | -0.97 |
| Stratum 2: 33.6 g/d Patiromer | -0.92 |
Least squares mean changes from Baseline to Week 8/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 8 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.47 |
| Stratum 1: 25.2 g/d Patiromer | -0.54 |
| Stratum 2: 16.8 g/d Patiromer | -0.88 |
| Stratum 2: 25.2 g/d Patiromer | -0.95 |
| Stratum 2: 33.6 g/d Patiromer | -0.91 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.54 |
| Stratum 1: 16.8 g/d Patiromer | -0.44 |
| Stratum 1: 25.2 g/d Patiromer | -0.50 |
| Stratum 2: 16.8 g/d Patiromer | -1.00 |
| Stratum 2: 25.2 g/d Patiromer | -0.96 |
| Stratum 2: 33.6 g/d Patiromer | -1.17 |
(NCT01371747)
Timeframe: Week 52 or Last Patiromer Dose (if Occurred before Week 52) to Following up Visit Plus 7 Days
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 0.36 |
| Stratum 1: 16.8 g/d Patiromer | 0.22 |
| Stratum 1: 25.2 g/d Patiromer | 0.30 |
| Stratum 2: 16.8 g/d Patiromer | 0.41 |
| Stratum 2: 25.2 g/d Patiromer | 0.39 |
| Stratum 2: 33.6 g/d Patiromer | 0.58 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 100 |
| Stratum 1: 16.8 g/d Patiromer | 100 |
| Stratum 1: 25.2 g/d Patiromer | 98.4 |
| Stratum 2: 16.8 g/d Patiromer | 91.7 |
| Stratum 2: 25.2 g/d Patiromer | 95.8 |
| Stratum 2: 33.6 g/d Patiromer | 95.5 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 95.2 |
| Stratum 1: 16.8 g/d Patiromer | 90.8 |
| Stratum 1: 25.2 g/d Patiromer | 81.3 |
| Stratum 2: 16.8 g/d Patiromer | 79.2 |
| Stratum 2: 25.2 g/d Patiromer | 91.7 |
| Stratum 2: 33.6 g/d Patiromer | 77.3 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 86.3 |
| Stratum 1: 16.8 g/d Patiromer | 81.6 |
| Stratum 1: 25.2 g/d Patiromer | 88.9 |
| Stratum 2: 16.8 g/d Patiromer | 86.7 |
| Stratum 2: 25.2 g/d Patiromer | 89.5 |
| Stratum 2: 33.6 g/d Patiromer | 93.3 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | Days (Median) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 4 |
| Stratum 1: 16.8 g/d Patiromer | 4 |
| Stratum 1: 25.2 g/d Patiromer | 4 |
| Stratum 2: 16.8 g/d Patiromer | 8 |
| Stratum 2: 25.2 g/d Patiromer | 7.5 |
| Stratum 2: 33.6 g/d Patiromer | 8 |
(NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 665 |
| Losartan 150 mg | 635 |
(NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 826 |
| Losartan 150 mg | 762 |
(NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 889 |
| Losartan 150 mg | 828 |
Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure. (NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 1085 |
| Losartan 150 mg | 1037 |
(NCT00090259)
Timeframe: Entire follow-up (median = 4.7 years)
| Intervention | Participants (Number) |
|---|---|
| Losartan 50 mg | 503 |
| Losartan 150 mg | 450 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
64 reviews available for losartan and Cardiac Failure
| Article | Year |
|---|---|
[Hypertension, hypertensive heart disease and heart failure. Role of loop diuretics].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2008 |
Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2011 |
Pharmacokinetic evaluation of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Heart Failure; H | 2011 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
[Antihypertensive treatment in patients with diabetes mellitus].
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Bosentan; Diabetes Complications; Endothel | 2002 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2003 |
[Treatment for diastolic failure].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphe | 2003 |
[Blocker of angiotensin-1 receptor antagonist losartan. Part III. Experience in therapy for chronic heart failure and after acute myocardial infarction].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Heart Failure; Humans; Los | 2003 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Fai | 2003 |
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2003 |
Valsartan for the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Diabetic Nephro | 2004 |
Pharmacological treatment and prevention of heart failure in the diabetic patient.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diab | 2004 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
[Management of hypertensive patients with cardiovascular damage].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
[Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2005 |
A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2005 |
Beta-blockers in heart failure: is more better?
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
[ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart | 2005 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[J-ELAN study (effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension)].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2007 |
[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cli | 2007 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
Anti-angiotensin therapy: new perspectives.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; | 2007 |
[Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2008 |
Angiotensin receptor antagonists as a treatment for hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Heart Failure; Humans | 1994 |
Losartan in heart failure: preclinical experiences and initial clinical outcomes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1994 |
Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Diseas | 1993 |
New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clini | 1993 |
Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1996 |
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
[Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1996 |
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 1997 |
[Angiotensin receptor antagonist for therapy of patients with hypertension].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 1997 |
Angiotensin II antagonism: a new avenue of hypertension management.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; | 1997 |
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
[New therapeutic perspectives associated with the introduction of angiotensin II receptor antagonists].
Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Cardiovascular Diseases; Clinical Tria | 1997 |
The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study.
Topics: Aged; Aging; Angiotensin Receptor Antagonists; Antihypertensive Agents; Evaluation Studies as Topic; | 1998 |
[Pathophysiological function of angiotensin II AT1 and AT2 receptors and clinical application of AT1 antagonists].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1998 |
[Losartan--a nonpeptide antagonist of angiotensin-II receptors in the treatment of heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cardiovascular Agents; Drug Evaluation, P | 1998 |
Drugs, heart failure and quality of life: what are we achieving? What should we be trying to achieve?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 1999 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1999 |
[Pharmacological characteristics and clinical application of losartan, an orally active AT1 angiotensin II receptor antagonist].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Chronic Disease; Clinical Trials | 1999 |
[ACE inhibitors or AT1 receptor antagonists?].
Topics: Age Factors; Aged; Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme In | 1999 |
Cardioprotective effect of angiotensin II receptor antagonists.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Age | 1999 |
Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1998 |
Losartan: a review of its use, with special focus on elderly patients.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Heart Failure; Humans; Hypertension; Losartan | 2000 |
Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Confidence Intervals; Controlled C | 2000 |
[Angiotensin-II-receptor antagonists for cardiac insufficiency].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimid | 2000 |
New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2001 |
The role of angiotensin receptor blockers in the management of chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bradykin | 2001 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2001 |
[Angiotensin I receptor blockers for heart failure].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2001 |
Diastolic dysfunction as a cause of exercise intolerance.
Topics: Animals; Antihypertensive Agents; Diastole; Dogs; Exercise Tolerance; Heart Failure; Humans; Losarta | 2000 |
[Can Sartane help a failing heart? AT1-receptor antagonists in cardiac insufficiency].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Heart Failure; Hemodynamics; Hum | 2001 |
The role of losartan in the management of patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; L | 2001 |
Hypertensive pulmonary oedema is due to diastolic dysfunction.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Diastole; Echocardiography, Doppler; Heart Fa | 2001 |
[Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2001 |
Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical | 2002 |
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; | 2001 |
79 trials available for losartan and Cardiac Failure
| Article | Year |
|---|---|
High- versus low-dose losartan and uric acid: An analysis from HEAAL.
Topics: Heart Failure; Humans; Hyperuricemia; Losartan; Stroke Volume; Uric Acid; Ventricular Function, Left | 2023 |
Acute effects of angiotensin-converting enzyme inhibition versus angiotensin II receptor blockade on cardiac sympathetic activity in patients with heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; | 2017 |
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Diabe | 2018 |
Effects of exercise training on SFO-mediated sympathoexcitation during chronic heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Heart; Heart Failu | 2014 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study.
Topics: Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Drug Delivery Systems; Female; Follow- | 2014 |
Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Cardiac Outp | 2014 |
Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.
Topics: Angiotensin Receptor Antagonists; Dose-Response Relationship, Drug; Follow-Up Studies; Glomerular Fi | 2015 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure | 2015 |
Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Det | 2015 |
Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial.
Topics: Aged; Biomarkers; Cardiovascular Agents; Fibrinolysis; Heart Failure; Humans; Losartan; Middle Aged; | 2016 |
Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Data Interp | 2008 |
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study.
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography; Female; Heart Fai | 2009 |
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Double-Blind Method | 2009 |
Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without β-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography | 2011 |
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
Topics: Aged; Angiotensin Receptor Antagonists; Chronic Disease; Drug Synergism; Drug Therapy, Combination; | 2011 |
Racial differences in incident heart failure during antihypertensive therapy.
Topics: Aged; Antihypertensive Agents; Asian; Black or African American; Blood Pressure; Electrocardiography | 2011 |
Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2012 |
Effect of changing heart rate during treatment of hypertension on incidence of heart failure.
Topics: Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiog | 2012 |
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Failure; Humans; Hypertens | 2012 |
A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor t
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Meth | 2012 |
Do high doses of AT(1)-receptor blockers attenuate central sympathetic outflow in humans with chronic heart failure?
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Female; Heart Failure; Humans; Losartan; Male; | 2013 |
Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Dose-Response Relationship, Drug; Double- | 2012 |
Effects of combined treatment with enalapril and losartan on myocardial function in heart failure.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dose- | 2002 |
Effects of chronic subdepressor dose of angiotensin II type 1 receptor antagonist on endothelium-dependent vasodilation in patients with congestive heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Dose-Response Relationship, Drug; Endothelium, Vascular; Fem | 2002 |
What is the meaning of LIFE? Implications of the Losartan Intervention for Endpoint reduction in hypertension trial for heart failure physicians.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Endpoint Determination; Heart Fai | 2002 |
Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Cross-Over Studies; Diuretics; Double | 2003 |
Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Humans; Hyperventil | 2004 |
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme | 2004 |
Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bl | 2004 |
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiovasc | 2004 |
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2004 |
B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
Topics: Adolescent; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bradykinin B1 R | 2005 |
Soluble CD40 ligand in acute and chronic heart failure.
Topics: Acute Disease; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2005 |
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Heart Failure; Humans; Losartan; | 2005 |
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2006 |
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2005 |
Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2007 |
Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2007 |
Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Electrocardiography, Ambulatory; Female; Follow-Up Studies; | 2007 |
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blin | 2008 |
Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Diseas | 1995 |
Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Fem | 1995 |
Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Double-Blind | 1994 |
Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Dr | 1993 |
Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS).
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Doub | 1996 |
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 1997 |
Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compound | 1997 |
Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin Recept | 1997 |
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiomyopathy, Dilated; | 1997 |
Pharmacokinetics of intravenous and oral losartan in patients with heart failure.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Cross-Over Studies; Female; Half-Life; Heart F | 1998 |
Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enalapril; Exerci | 1998 |
Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; End | 1998 |
Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blin | 1999 |
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1999 |
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Cause of Death; D | 1999 |
Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 1999 |
Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Cardiotonic Agent | 1999 |
The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Drug | 1999 |
Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cross-Over | 1999 |
ACE inhibitors still the drug of choice for heart failure--and more.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Death, Sudden, Cardiac | 1999 |
[Losartan in therapy of chronic heart failure].
Topics: Adult; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Diuretics; Drug Therapy, Combinatio | 2000 |
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Met | 2000 |
Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Ag | 2000 |
[Interview with the author of ELITE II. Cave: small studies of fatal illnesses].
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1999 |
[A-II blocker or ACE inhibitor in heart failure? Captopril can't be beat].
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1999 |
Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic | 1999 |
Is losartan superior to captopril in reducing all-cause mortality in elderly patients with symptomatic heart failure?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Female; Heart Failur | 2000 |
[Prospects of endothelial dysfunction reversion in patients with congestive heart failure].
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Brachial Artery; Ena | 2000 |
[The ELITE 2 study].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Met | 2000 |
Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captop | 2000 |
Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiote
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; | 2001 |
Radial artery flow-mediated dilatation in heart failure patients: effects of pharmacological and nonpharmacological treatment.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Drug Administration S | 2001 |
Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Doub | 2001 |
[Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
199 other studies available for losartan and Cardiac Failure
| Article | Year |
|---|---|
Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
Topics: Acute Coronary Syndrome; ADAM17 Protein; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angio | 2021 |
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
Investigation of the Antihypertrophic and Antifibrotic Effects of Losartan in a Rat Model of Radiation-Induced Heart Disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chymases; Disease Models, Animal; Heart Failure; H | 2021 |
High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
Topics: Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hyperkalemia; Hypokalemia; Losartan | 2023 |
Angiotensin II type 2 receptor agonist treatment of doxorubicin induced heart failure.
Topics: Animals; Doxorubicin; Heart Failure; Losartan; Rats; Receptor, Angiotensin, Type 2; Stroke Volume; V | 2023 |
Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Electrocardiography; Heart Failure; Hum | 2023 |
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2023 |
The treatment with trandolapril and losartan attenuates pressure and volume overload alternations of cardiac connexin-43 and extracellular matrix in Ren-2 transgenic rats.
Topics: Animals; Blood Pressure; Connexin 43; Extracellular Matrix; Fistula; Heart Failure; Hypertension; Lo | 2023 |
Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Fail | 2021 |
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2022 |
Interaction between interleukin‑6 and angiotensin II receptor 1 in the hypothalamic paraventricular nucleus contributes to progression of heart failure.
Topics: Animals; Corticotropin-Releasing Hormone; Disease Progression; Heart Failure; Interleukin-6; Losarta | 2017 |
Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Biphen | 2018 |
Inhibition of AT1 receptors by losartan affects myocardial slow force response in healthy but not in monocrotaline-treated young rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Female; Heart Failure; Losartan; Male; Monocrotali | 2018 |
Increased cardiac sympathetic nerve activity in ovine heart failure is reduced by lesion of the area postrema, but not lamina terminalis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Postrema; Arterial Pressure; Baroreflex; Dise | 2018 |
Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Animals; Brain; Dise | 2019 |
Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Heart Failure; Kidney; Kidney Function Tests; Losa | 2013 |
Heart failure and angiotensin II modulate atrial Pitx2c promotor methylation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Azacitidine; Cell Line, Tumor; Decitabine | 2013 |
An Angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Fibrillation; Atrial Remodeling; Disease Models, A | 2013 |
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo | 2013 |
Interaction between AT1 receptor and NF-κB in hypothalamic paraventricular nucleus contributes to oxidative stress and sympathoexcitation by modulating neurotransmitters in heart failure.
Topics: Animals; Heart Failure; Losartan; Male; Neurotransmitter Agents; NF-kappa B; Oxidative Stress; Parav | 2013 |
Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: implications in heart failure.
Topics: Aldehyde Dehydrogenase; Angiotensin II; Animals; Biphenyl Compounds; Catalase; Enzyme Activation; He | 2013 |
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Mal | 2013 |
Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Denmark; Drug Costs; D | 2013 |
Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2014 |
Interaction between interleukin-1 beta and angiotensin II receptor 1 in hypothalamic paraventricular nucleus contributes to progression of heart failure.
Topics: Animals; Corticotropin-Releasing Hormone; Disease Models, Animal; Disease Progression; gamma-Aminobu | 2014 |
Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Denmark; Female; Heart F | 2014 |
Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Bisoprolol | 2014 |
Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cholinesterase Inhibitors; Chronic Disease; Diseas | 2014 |
Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
Topics: Aged; Antihypertensive Agents; Electrocardiography; Female; Heart Failure; Humans; Hypertension; Hyp | 2014 |
Donepezil, a potential therapeutic agent for heart failure.
Topics: Animals; Heart Failure; Indans; Losartan; Myocardial Infarction; Piperidines | 2015 |
Healing the orphaned heart: heart failure in a patient with glucose-6-phosphate dehydrogenase deficiency.
Topics: Aged; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Female; Glucosephosphate Dehydrogenase | 2015 |
Effect of angiotensin II on voltage-gated sodium currents in aortic baroreceptor neurons and arterial baroreflex sensitivity in heart failure rats.
Topics: Angiotensin II; Animals; Aorta; Arteries; Baroreflex; Chronic Disease; Disease Models, Animal; Heart | 2015 |
TSC-22 up-regulates collagen 3a1 gene expression in the rat heart.
Topics: Animals; Antihypertensive Agents; Cells, Cultured; Collagen Type III; Female; Gene Expression; Gene | 2015 |
Sympathoexcitation in Rats With Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus.
Topics: 3' Untranslated Regions; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding S | 2016 |
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Decision Support Techniques; Disease | 2016 |
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Decision Support Techniques; Disease | 2016 |
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Decision Support Techniques; Disease | 2016 |
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Decision Support Techniques; Disease | 2016 |
Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade.
Topics: Acute Kidney Injury; Aged; Albuminuria; Blood Pressure; Drug Therapy, Combination; Female; Glomerula | 2016 |
A novel role for miR-133a in centrally mediated activation of the renin-angiotensin system in congestive heart failure.
Topics: 3' Untranslated Regions; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Cell Lin | 2017 |
[A 60-year-old man with heart failure, dry cough and elevated INR values].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Coronary Th | 2008 |
Mitogen-activated protein kinases mediate upregulation of hypothalamic angiotensin II type 1 receptors in heart failure rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Disease Models, Animal; Heart F | 2008 |
All clinical trials are not created equal: The dilemma of HEAAL.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Hu | 2008 |
The acute and chronic effects of losartan in heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Controlled Clinical Trials | 1995 |
Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Down-Regul | 1995 |
The relationship between heart rate reserve and oxygen uptake reserve in heart failure patients on optimized and non-optimized beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; | 2009 |
Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Citrulline; Enzyme Inhibito | 2009 |
Noninvasive imaging of angiotensin receptors after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Biomarkers; Disease | 2008 |
Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; C | 2009 |
Cardiac secretion of atrial and brain natriuretic peptides in acute ischaemic heart failure in pigs: effect of angiotensin II receptor antagonism.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; A | 1997 |
[Hypertension and the heart].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Cardiovascula | 2009 |
Enhanced angiotensin-mediated excitation of renal sympathetic nerve activity within the paraventricular nucleus of anesthetized rats with heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, An | 2009 |
[Effect of renin-angiotensin system inhibitors on the density of myocardial, pericardial and pulmonary rat mast cells under experimental heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Cou | 2009 |
Optimising management of chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chroni | 2009 |
HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; American Heart Association; Antihypertensive Agents; Carbazoles; | 2010 |
Alterations of cardiac ERK1/2 expression and activity due to volume overload were attenuated by the blockade of RAS.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2010 |
[Effects of losartan and simvastatin on collagen content, myocardial expression of MMP-2 mRNA, MMP-9 mRNA and TIMP-1 mRNA, TIMP-2 mRNA in pressure overload rat hearts].
Topics: Animals; Gene Expression Regulation; Heart Failure; Losartan; Male; Matrix Metalloproteinase 2; Matr | 2009 |
Chronic AT1 receptor blockade normalizes NMDA-mediated changes in renal sympathetic nerve activity and NR1 expression within the PVN in rats with heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cell Line, Tumor; Dose-Response | 2010 |
High-dose versus low-dose losartan in patients with heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Losartan; Uric Acid | 2010 |
High-dose versus low-dose losartan in patients with heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Losartan; Myocardium | 2010 |
A consistency-adjusted alpha-adaptive strategy for sequential testing.
Topics: Algorithms; Biostatistics; Captopril; Clinical Trials as Topic; Data Interpretation, Statistical; Di | 2010 |
Changes in metabolic profile and population of skeletal muscle fibers of mice overexpressing calsequestrin: influence of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Calsequestrin; Female; Glycerolphosph | 2011 |
Losartan reduces mortality in a genetic model of heart failure.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 Receptor Blockers; Animals; Calsequestri | 2010 |
Getting better value from the NHS drug budget.
Topics: Angiotensin II Type 1 Receptor Blockers; Budgets; Drugs, Generic; Health Care Reform; Heart Failure; | 2010 |
Association of candesartan vs losartan with all-cause mortality in patients with heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cause | 2011 |
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.
Topics: Adrenal Glands; Aldosterone; Animals; Arrestins; beta-Arrestin 1; beta-Arrestins; Cell Line; Disease | 2011 |
Costarring statins with ARBs: going to be a smash hit?
Topics: Angiotensin Receptor Antagonists; Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; | 2011 |
Waste not, want not: free money, moral hazard and value-based prescribing.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; | 2011 |
Easy money? Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; | 2011 |
[The HEAAL study].
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Losartan; Multicenter Studies as Top | 2010 |
Heart failure prevention is the best option to stem high costs and disease burden: research for more effective heart failure treatment is needed.
Topics: Antihypertensive Agents; Black or African American; Cost of Illness; Health Care Costs; Heart Failur | 2011 |
[Remarkable results with candesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Dose-Response Relations | 2011 |
Candesartan vs losartan and mortality in patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Europe; Guideline Adherence; H | 2011 |
Candesartan vs losartan and mortality in patients with heart failure.
Topics: Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Heart Failure; Humans; Losarta | 2011 |
[Effect of losartan, lisinopril and their combination on hemodynamics and morphofunctional parameters of the heart in patients with chronic cardiac failure].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic | 2011 |
Intracrine action of angiotensin II in the intact ventricle of the failing heart: angiotensin II changes cardiac excitability from within.
Topics: Action Potentials; Angiotensin II; Animals; Cell Separation; Cricetinae; Heart Failure; Heart Ventri | 2011 |
Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Female; Heart Failure; Humans; Hypertension | 2011 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confoun | 2012 |
Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure.
Topics: Angiotensin II; Animals; Body Weight; Brain; Brain Stem; Electrocardiography; Heart; Heart Failure; | 2011 |
Decreased nNOS in the PVN leads to increased sympathoexcitation in chronic heart failure: role for CAPON and Ang II.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anima | 2011 |
Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Benzim | 2011 |
Critical evaluation of the optimal medical therapy in the cardiac resynchronization therapy candidates--single centre experience.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2011 |
Sympathetic signatures of cardiovascular disease: a blueprint for development of targeted sympathetic ablation therapies.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Heart; Heart Failure; Kidney; Losartan; Sympatheti | 2012 |
Central angiotensin type 1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoradiography; Baroreflex; Blood Pressure; Disea | 2012 |
Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Echocardiography; Electrocardiogra | 2012 |
Association of treatment with losartan vs candesartan and mortality among patients with heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2012 |
Subtle issues in model specification and estimation of marginal structural models.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; Humans; | 2012 |
Exercise training normalizes enhanced sympathetic activation from the paraventricular nucleus in chronic heart failure: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Heart Failure; Hea | 2012 |
Losartan vs candesartan for heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Female; Heart Failure; Humans; Losartan; Ma | 2012 |
Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium-Binding Proteins; Cardiomegaly; Catecholam | 2012 |
Adverse events in HEAAL: when to hold and when to fold.
Topics: Angiotensin II Type 1 Receptor Blockers; Female; Heart Failure; Humans; Losartan; Male | 2012 |
Exercise training and losartan improve endothelial function in heart failure rats by different mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biological Factors; Disease Models, Animal; Dose-R | 2013 |
Central AT1 receptors are involved in the enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure.
Topics: Anesthetics, Local; Angiotensin II; Animals; Anti-Arrhythmia Agents; Bradykinin; Capsaicin; Heart Fa | 2002 |
[Respiratory and renal functions and blood electrolytic composition in patients with pulmonary tuberculosis in the treatment of heart failure].
Topics: Adult; Anti-Arrhythmia Agents; Antitubercular Agents; Electrolytes; Female; Heart Failure; Humans; K | 2002 |
[Addition of an angiotensin II receptor blocker to maximal dose of ACE inhibitors in heart failure].
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
Impaired responsiveness of renal mechanosensory nerves in heart failure: role of endogenous angiotensin.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Dinoprostone; Heart Failure; Kidney; Losa | 2003 |
[Is it real to replace angiotensin converting enzyme inhibitors as basic remedy in the treatment of chronic heart failure?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Clinical Trials as Topic; Dose | 2002 |
Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Aldosterone; Angiotensin Receptor Antagonists; Angio | 2002 |
Are angiotensin II receptor antagonists indicated in chronic heart failure?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Deat | 2003 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Bip | 2003 |
Losartan corrects abnormal frequency response of renal vasculature in congestive heart failure.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Heart Failure; Kidney; Losartan; M | 2003 |
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2003 |
Congestive heart failure: guidelines for the primary care physician.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Diagnosis, Differential; Diuretics; Heart Failu | 2003 |
Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction.
Topics: Animals; Antihypertensive Agents; Antioxidants; Catalase; Enzymes; Gene Expression; Glutathione Pero | 2003 |
Losartan inhibits myosin isoform shift after myocardial infarction in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weight; Heart Failure; Hemo | 2003 |
[ACE inhibitors and/or sartans in heart failure: is there a difference?].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; L | 2003 |
Induction of myocardial biglycan in heart failure in rats--an extracellular matrix component targeted by AT(1) receptor antagonism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biglycan; Extracellular M | 2003 |
ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; | 2003 |
Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blotting, Northern; Blotting, Western; Calci | 2003 |
Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure.
Topics: Adenoviridae; Animals; Antihypertensive Agents; Brain; Genetic Vectors; Heart Failure; Humans; Injec | 2004 |
[Prognostic value of elevation of plasma concentration of atrial natriuretic peptide in patients with cardiac failure. Results of a cohort study].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; At | 2003 |
[New options against undertreatment].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Top | 2003 |
Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.
Topics: Amlodipine; Animals; Doxorubicin; Endothelin-1; Gastric Mucosa; Heart Failure; Losartan; Male; Mice; | 2004 |
Changes in skeletal muscle SR Ca2+ pump in congestive heart failure due to myocardial infarction are prevented by angiotensin II blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2004 |
Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Ditiocarb; Heart F | 2004 |
Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
Topics: Adenylyl Cyclases; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Enalap | 2004 |
Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment.
Topics: Animals; Antihypertensive Agents; Calcium; Calcium-Transporting ATPases; Cardiomegaly; Enalapril; Ge | 2005 |
Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
Topics: Adrenergic beta-Agonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anim | 2005 |
Modification of sarcolemmal Na+-K+-ATPase and Na+/Ca2+ exchanger expression in heart failure by blockade of renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Ca(2+) Mg(2+)-ATPase; Gene Expression Regulation; | 2005 |
[Changes of collagen expression of pulmonary arteries and heart ventricles and intervention of fosinopril and losartan in rats with heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Collagen; Female; Fosinopril; Heart Failure; Hear | 2004 |
Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials.
Topics: Aged; Captopril; Clinical Trials as Topic; Confidence Intervals; Data Interpretation, Statistical; F | 2006 |
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; C | 2005 |
Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chemokine CCL2; Creatinine; Female; Heart | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Effects of losartan + L-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Brachial Artery; Coro | 2006 |
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.
Topics: Aged; Body Mass Index; Captopril; Cardiovascular Agents; Female; Heart Failure; Humans; Hydroxymethy | 2006 |
[Effect of losartan on sarcoplasmic reticulum Ca2+ handing proteins in heart failure rabbit].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium; Calcium Channels; Calmodulin; Female; Hea | 2006 |
Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2007 |
Heart failure treatment profile at the beta blockers era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Carbazoles; Carved | 2007 |
Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan.
Topics: Adenylate Kinase; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Combined Modality Th | 2007 |
Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure.
Topics: 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Angiotensin II Type 1 Receptor Blockers; Animals; Cy | 2007 |
Reactive oxygen species in the paraventricular nucleus mediate the cardiac sympathetic afferent reflex in chronic heart failure rats.
Topics: Afferent Pathways; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Heart; Heart Fa | 2007 |
The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Blood Pressure; D | 2008 |
Comparison of the cardioprotective effects of cardos and losartan in rats with experimental chronic cardiac insufficiency.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Cardiotonic Agents; Chronic Disease; D | 2007 |
Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease | 2008 |
Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cyclic N-Oxides; Cytokines; Disease Models, Animal | 2008 |
ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure.
Topics: Angiotensin Receptor Antagonists; Animals; Arteries; Baroreflex; Biphenyl Compounds; Heart Failure; | 1995 |
Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus.
Topics: Acute Disease; Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyperten | 1995 |
Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inh | 1994 |
[Medical angiotensin II-receptor blockade in hypertension and heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1995 |
Human cardiac fibroblasts express an angiotensin receptor with unusual binding characteristics which is coupled to cellular proliferation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cell Division; Cells, Cultured | 1994 |
Losartan improves the natriuretic response to ANF in rats with high-output heart failure.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Cyclic GMP | 1994 |
Renin-angiotensin system and cell communication in the failing heart.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Cells, Cultured; Cricetinae; E | 1996 |
Blockade of the renin-angiotensin system in heart failure in conscious dogs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
Angioedema associated with angiotensin II receptor antagonist losartan.
Topics: Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Female; H | 1997 |
Losartan versus captopril in elderly patients with heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 1997 |
Losartan versus captopril in elderly patients with heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 1997 |
Losartan versus captopril in elderly patients with heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 1997 |
Losartan versus captopril in elderly patients with heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 1997 |
Angiotensin II receptor antagonists, elite drugs (or not) for patients with heart failure or hypertension?
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Heart Failure; Human | 1997 |
ELITE study raises losartan's profile in heart failure therapy debate.
Topics: Aged; Biphenyl Compounds; Cardiovascular Agents; Female; Heart Failure; Hospitalization; Humans; Imi | 1997 |
[Angiotensin II antagonist for heart insufficiency].
Topics: Adrenergic beta-Antagonists; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors | 1997 |
[New therapeutic principle in the management of cardiac insufficiency: A II antagonists. Results of the ELITE study (Evaluation of Losartan In The Elderly)].
Topics: Aged; Angiotensin II; Anti-Arrhythmia Agents; Female; Heart Failure; Humans; Losartan; Male; Renin-A | 1997 |
[Angiotensin-II-antagonism: new hope for the management of cardiac insufficiency].
Topics: Age Factors; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 1997 |
Evaluation of Losartan in the Elderly (ELITE) Trial: clinical implications.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopri | 1997 |
Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Baroreflex; Blood Pressure; Heart; Heart | 1998 |
The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Brain; Captopril; Evalua | 1998 |
Angiotensin II receptor antagonists for heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1998 |
[Value of angiotensin II-antagonists].
Topics: Angiotensin II; Anti-Arrhythmia Agents; Antihypertensive Agents; Heart Failure; Humans; Losartan; Re | 1998 |
[Effect of renitek--an ACE inhibitor--versus cozaar--an angiotensin I receptors antagonists--on morphofunctional state of left ventricular myocardium in patients with symptomatic cardiac insufficiency].
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 1999 |
AT1-receptor antagonists for the treatment of chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Baroreflex; Bloo | 1999 |
Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin II; Antihypertensive Agents; Blood Pressure; Chronic Disease; C | 1999 |
Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2000 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
AT1-receptor blockers.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart | 2000 |
ELITE II. AT1-blockers not better, but more tolerable than ACE-inhibitors.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ca | 2000 |
Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Capt | 2000 |
[Heart failure as a cardiac symptom of sarcoidosis. Successful treatment of heart failure with steroids, digitalis and an angiotensin-1-receptor antagonist in sarcoidosis].
Topics: Adult; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Cardiomyopathies; Digitoxin; Drug Therapy, | 2000 |
All that glitters is not gold.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Heart Failure; Humans; | 2000 |
Does losartan decrease all-cause mortality more than placebo or first-generation ACE inhibitors for patients with moderate to severe heart failure?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Heart Failure; Humans; Losartan; | 2000 |
Effects of losartan treatment on cardiac autonomic control during volume loading in patients with DCM.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Autonomic Nervous System; Blood Pressure; Cardiomyopa | 2000 |
Blockade of central angiotensin II does not affect the reduction in renal sympathetic nerve activity following a volume load in heart failure rabbits.
Topics: Angiotensin II; Animals; Antibiotics, Antineoplastic; Blood Pressure; Blood Volume; Doxorubicin; Ele | 2000 |
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Circadia | 2000 |
Comparison of losartan and captopril in ELITE II.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Heart Failure; Humans; | 2000 |
Comparison of losartan and captopril in ELITE II.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2000 |
Comparison of losartan and captopril in ELITE II.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 2000 |
Comparison of losartan and captopril in ELITE II.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Administ | 2000 |
Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro.
Topics: Active Transport, Cell Nucleus; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihyper | 2000 |
[Current role of angiotensin II antagonists in the treatment of heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Clinical Trials as Topic; Drug | 2000 |
Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure.
Topics: Adult; Aged; Capillary Permeability; Enalapril; Heart Failure; Hemodynamics; Humans; Losartan; Male; | 2001 |
Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause o | 2001 |
The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure.
Topics: Acetamides; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Function, Left; Diasto | 2001 |
Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
Topics: Acetylcholine; Aged; Angina Pectoris; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme I | 2001 |
Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats.
Topics: Angiotensin Receptor Antagonists; Animals; Catalase; Glutathione Peroxidase; Heart Failure; Lipid Pe | 2001 |
Sodium intake influences hemodynamic and neural responses to angiotensin receptor blockade in rostral ventrolateral medulla.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |
Angiotensin II type 1 receptor blockers and congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2001 |
Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Calcium; Female; Heart Failure; | 2001 |
Effect of losartan on circulating TNFalpha levels and left ventricular systolic performance in patients with heart failure.
Topics: Aged; Antihypertensive Agents; Female; Heart Failure; Humans; Losartan; Male; Middle Aged; Stroke Vo | 2001 |
Are angiotensin II receptor blockers indicated in chronic heart failure?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disea | 2002 |
Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Aquaporin 2; Aquaporin | 2002 |
[Stress intolerance in diastolic dysfunction. A case for AT1 blocker?].
Topics: Antihypertensive Agents; Diastole; Exercise Test; Heart Failure; Humans; Hypertension; Hypertrophy, | 2002 |
Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure.
Topics: Angiotensins; Animals; Anti-Arrhythmia Agents; Calcium Signaling; Cardiomegaly; Cell Separation; Cel | 2002 |
Contemporary medical options for treating patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure.
Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Capto | 2002 |